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Abstract of Dissertation

Cydk od~nosine 3',5'-monophosphate (cAMP) wns first described as the mediator of the
glycogenolytic effed c)f epinephrine und glur:agon in the liver almost two decades ago. It
ho~ since been found !hat cAMP may rnedial-e the effects of a number of hormones and neurohormones, 1::nd this ob5ervation has !t~d to the development of the second messernger hypothesis
of hormone action. Ac:wrding to the second l•1essenger thcor;·, the hormone or first messenger
bdngs 1nformC!tion to the eel!, whereas, the:: second messenger {cAMP) transfers this information
lnto intr..:~ce!lular events. More recent evidence hos described the existonce of on additional
second mess.enger, C}•clic guanosine 3' ,5'-monophosphole (~GMP). In some instances, the
physiolcgicol response produc:t:d by a rise in the intraceliular concentration cf cGMP is
c-pposih.'! io that elicih<;d by cAMP. Thi~ has led to the hypothesis that these cydic nucleotides have ontogor.ist regulatory roles in ce!l function.
cAJ.i,p ond cGMP hove been proposed to be second messengers responsible, at least in part,
for the actions of hormones which modify vascular smool·h muscle tone. The current hypothesis
describing this relation!ihip envision!i an in-crease in vascular tone to be the result of either an
increase in the tissue levels of cGMP oro decrea~e in c.A.MP, while, an increase in cAMP or
a dec:rcose in cGMP leads to the relaxation of va$cular smooth muscle. There hove bP.en
reCP.:'"lt repc.rts of an elevr..,ted ratio of cGMP to cAMP in the vascular tissues of the stress, DOCA,
neurogenic, and spontaneously hypertensive rats which couid explain the increased vascular
sm~oth muscle tone (lnd pe.-ipheral resistance in thnse animals. The enzymatic m·echanisms
resp:m5ible for the c.!~ered cyclic nucleotide metabolism was unclear. Thus, one of the aims
of this re~t-:orch wa':. not only to clarify, but l·o give additional insight concerning the relative
roles of <.'deny! cyclme c;nd phosphodiesterase (PDE) activ~ty in regulating the irttracellular
levels of cAMP in th~ aorta er the spontar.eously hypert~nsive rot (SHR). A second objective
wos to tie~err;-,Jne 'li·hether there was a correlation between the level of blood pressure in
the SHR and the ratio of cGMP to cAMP in the aor1a.
Using a combination of cell-free and intact cell as~ay system:;, we have demon!itrated that
the activity of adenyl cyclase, beth basol and beta-adrenergic stimulated, was si9nificantly
de~;;reased in the SHR aort1.1. The app<1rent affinity of isoproterenol for the receptor, the k01
for A.TP, and the mrJgnesium and pH dependent ocl·ivlties were sim;lar to that observed in
the control. There was o decreas~ in the activity of the low km form of POE in the SHR aorta,
hoW•2VtH, th<~re was no difference in the apparent affinity for cAMP or in tl1e tTY-lgnesium or
pH dependent activitie~. On the basis of this data, we would Bke ~o propose that the low
cJ\Iv\P level~ in the SH!\ result from a decreasE:: ln rhe th.s conccnlf.:~hon of adenyl cyclase
protein in !"he var.cuior 5mocth mu~cle, The concentration of PDE protein has apparently decremeJ secondarily tc be consistant with the new St(!O·Jy-state lew.! is of cAMP.
0

Compmed to i·he normoten~ive control, cAMP l~vei:. in the SHR oorlo were initiol!y low
in trc ;:n;hypertenslvt: S!iR end decreas.eJ further as tne animal grew older and ihe blooG pressure i1~crem~d. The levels in the cc-ntrol rem!Jincd com:tant throughout the ~'Jme period. At
!he p1~>:hypertomlve ag8, cGMP conc.enh·..nic~rl in thE! SHR corta was simile..- lu t\v.::;f observed
in the c.onho!, b1.;t as the blood pressur~ increased in the SHR, cGMP remained ai J·his level,
wherea~, the concentration in age-matched normot~msive controb had diminished, Chronic
ontihyp>F...-tensive therapy in the mature SHR did not affect cAMP, but lowl'lred cGMP to the
ie ... els found in the normotensive vessel.· Based (,n these studies, it i!. suggested that the alteration
In c.A.VIP metabolism has occurred prior to the incr~ose in blood pressure, while cGMP levels
O<P. changing as a 1·esult of the hyperten~.ioP,
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INTRODUCTiON

Hypertension is said to exist when the systemic blood pressure is persistently
above the age-·adjusted normal ranges, and according to this cril'eria, it has been
estimated that approximately 23 million, or about 15% of the adult population
have some form of hypertensive disease.

Hypertension is a subtle, relatively a-

symptomatic condition, but many studies (1,2) have documented the secondary
complications that can result as a direct consequence of chronically elevated
arterial pressures. Depending upon the severity and duration of the hypertension,
one eventually observes

h~·aline

degeneration of the arterioles, arteriosclerosis

and atherosclerosis of the larger arterial vassels.

!n the !'earl, there i;

from hypertrophy to dilatation and eventual cardiac failure.

tl

progression

Insurance statistics

(3) have shown thGt there is a direct correlai·ion between the degree of hypertension and the probability of morbid and mortal events which are a consequence
of these secondary pathological changes. Fortunately, antihypertensive therapy
has been shown to be effective in reducing the incidence of the secondary comp!kctions which are inevitable consequences in the untrected hypertensive patient

(4).
In <lpprox.imcte!y 90% of al! patients with hypertension,
no. underlying organic
.
disecse is idenl·ified and this condition is described as essenHci or primary hypertension. The remaining number cf cases occur secondarily to other pathologies
such as adrenal cortical hyperfunctian, pheochromocytcma, rene.! vascular and
parenchymal diseases, coarctation of the aoita, or foxemia of pregnt:mcy.

2

Epidemiological studies have shown that genetic factors could be important
determinants in !he development of essential hypertension. Hypertension frequently affects members of the same family (5), and it has been estimated by
Piatt (6) that th<> probability of developing essential hypertension is increased
eight times in 1-h<o siblings of severely hypertensive parents. Certain racial
groups, most notably the American blacks, have a high incidence of severe
hypertensive disease (7); whereas in other populations, such as the islanders
of the South Pacific, there is a very low incidence (8). The prevalence in women
prior to menopause is about one-half of that observed in men (45-50 years of age)
but equals it above this age.
General Theories Concer~Ing the t:athoge~esis of Essential Hyr:_ert_ension

j
1

The regulation of the systemic arterial blood pressure is a reflection of the
interactions between several cardiovascular control systems which ultimately
regulate the relationship between cardiac output and t·he level of peripheral
vascular resistance. Essentio I hypertension, therefore, may be caused by an
increase in cardiac output, an increase in vmcular resistance, or both. There
is now ovePNhelming evidence that a decreme in the caliber of the arterial
resistance vessels with o subsequent rise in total vascular resistance is the major
hemodynamic abnormality in this form of hypertensive disease. Various
theories, which emphasize an alteration in one or more of these conl"rol systems,
have been proposed to explain the changes in vascular resistance •.
One of the major theories currently under investi,gation was proposed by
Guyton and his collegues (9). These invesl'igators have stressed the dominanr.e
of the kidney as a long t-erm regulator of the systemic blood pressure. It was
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suggested that a subtle defect in the ability of the kidney to excrete sodium and
water would neces>itate the development of higher systemic pressures to maintain
the equilibrium between the intake and output of salt and water. This defect
in the excretion ability of the kidneys could result from renal abnormalities
such as a change in the caliber of the afferent arterioles or a decrease in the
glomerular filtration coefficient.

Nonrenal abnormalities, such as an increase

in sympathetic ne1vous system activily or in the formation of angiotensin II,
could alter renal function by constricting the afferent arterioles of the kidneys.
The principal thesis of this proposed theory is that renal output in essential hypertension is norma I but due to a rena I pathology or nonrena I factors, the systemic
pressure must be considerably higher to maintain this normal excretion rate.
Other investigators, particularly Lamgh and coworkers (10), have emphasized
the importance of the renin-angiotensin-aldosl·erone axis as a major factor.
In the patients they have examined in their clinical studies, 57% had a normal
plasma renin activity (PRA), whereas, 16% had a high PRA, and 27% had an
activity much lower than the accepted norm. Those patients having an elevated
PRA were described as having marked vasoconstriction which was ascribed to
excessive cmgiotensin II formation.

Because the patients with a low PRA responded

bener to diuretic treatment than did the high PRA group, it was proposed that
the former group had an elevated plasma volume az their primary hemodynamic
abnormality. Those patients with the normal renin were presumed to have a
composite of vasoconstrictor and volume charactedstics.

It was additionally

proposed that the low PRA pal"ients have a lower incidence of hyperl"ension dependent complications, such as stroke and myocardial infarction, compared to
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those having a normal or high PRA, The major criticism of this theory has been
the inability of other inve,tigators to confirm these studies (1 I, 12, 13) and it has
been proposed (14) that the renin subgroups could represent different phases
of the same disease rather than distinct pathologies,

In spite of the controversy,

the irnmediclte clinical relevance was apparent, and some clinicians have been
attempting to diagnose and rationally treat essential hypertension based on these
criteria.
The other theory currently under investigotion integrates aspects of the
s:rmpCJthetic nervous system with that of local factors which modify vascular
smcoth muscle tone. The theory is based on the clinical studies of Widimsky (15),
Eich

:!

<::! (16), and Frohlich':.!" <::! (17) in which the temporal hemodynamic

pott<,rns were examined during the development of the hypertensive stal-e,

It

was noted that in young subjects there were wide fluctuations of blood pressure 'Nhich coincided with periods of increased cardiac r;u!·put in the presence of
a norma I periphera I vascular resistance. As the hypertension became more estc.blished, cardiac output returned to normal, whereas, the resistance to flow
incrcm.ed. The changes in vascular resistance were not uniform, but were most
pronounced in the renal, splanchnic, and cutaneous circulations.

Resistance

in !·he vasculm beds of the skeletol muscle actL'ally dec.-eased,
Coleman :_!

':! (18) have proposed that the ouslained increase in vascular resistance

represents an ottempt by the vasculature to normalize the increased perfusion
by local autoregulatory mechanisms. Alternatively, Foikow and his colleagues

(19) have stressed the importanGe of structural adaptations, such as medial
h)•perl-rophy, as J·he major compensatory mechanism to the increase in blood flow.
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An importont a.sp'loct of this theory is that lhe automonic neNous system, through
its sympathetic cm;m1ponenl, participates only in the initiation of the disease process
via an increase Jn cardiac output, and that other mechanisms are operating to
maintain the hype•i'ension through an increase in peripheral vascular tone.
Anim~L_Models

of Hypertension

The following is a brief description of the experimental animal models that
have been used as prototypes for hypertension as it is observed in man. The
importance of t·hes·e models cunno!· be underestimated bec(!use they have been an
indispensable aid in developing the concepts concerning the etiology ana pathogenesis of both primary and secondary types of hypertensive disease.
The classic model was developed by Goldblatt~ ~ (20) and has been extensively studied since its conception in 1934. The Go!dblatt procedure consists
of constricting one of the renal arteries, followed by surglcol removal of the
contralateral kidney. An alternative method has been to constrict both renal
arteries and produce what is known as "two kidney hypertension".

In the "one

kidney" Goldblatt hypertensive model, it is generally accepted that an increase
in plasma volume is the principal factor in tf-.e evolution of this hypertensive
condition, whereas, in the "two kidney" model an angiotensin II induced vasoconstriction is believed t·o play the dominant role (21). Because of the im··
portance of the renal vasculature in the etiology of the hypertensive condition,
the model has been useful in i·he understanding the various lypes of renal vascular
hypertension but its application to the study of essential hypertension is limited.
Another popular model system has been the induction of hypertension by
desoxycorticosterone (DOCA); a sodium retuining hormone of the adrenal cortex
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(22). The acute effects of DOCA are due to an expansion of the extrncellular
fluid, but the pressor response persists after discontinuing the treatment (23).
The mechanisms responsible for the maintenance of the pressor condil-ion are not
known, but could be the consequence of local autoregulatory mechanisms in the
peripheral vCJscufature. The clinicCJI correlate of DOCA hypertension is adrenal
cortical hyperfunction, but its relevance to essential hypertension is minimal.
Much of the concern regarding the appropriate model for essential hypertension
WCIS

temporarily allayed when Smirk and Hall (24) produced a genl'ically pre-

disposed colony of hypertensive rats.

Unfortunately, the frequency and degree

of hypertension was low and there was a low incidence of secondary pathologic
lesions.

For these reasons, the attracl"iveness of this model for essential hypertension

was diminished.
In 1963, Okamoto and Aoki (25) produced a genel'ic s1"rain of hype.-tensive rats
through selective inbreeding of the Wister Kyoto rat in which a severe form of
hypertension occurs in essentially 100% of the offspring. The hypertension develops spontaneously, increases rapidly with age, and results in the characteristic
hypert,ension dependent pathologies such as cardiac hypertrophy, arteria- and
atherosderosis.

It is quite certain that neither the sympathetic nervous system

(26,27) nor the renin-angiotensin pressor system (28) particapte in the maintenance
of hypertension in this model. All of these findings are very similar to those observed in the clinical sii!Jation with patients diagnosed as having essential hypertension.

It is generally accepted, therefore, thCit this model is currently the closest

prototype of essential hypertension as it occurs in man (29). This model, character··
istically known as· the spontaneously hypertensive rat (SHR), was used exclusively

7
\

1

I

1

in this study.
:{~scular

Reactivity in Essential Hypertension

Essential hypertension may well have a number of distinct initiating causes,
but in the final analysis, the persistence of an elevated blood pressure must I ie in
a change in the caliber of the arteriolar resistance vessels.

From this perspective,

the changes in vascular tone could result from (a) a neural or hormonal influence,
(b) structural changes that could decrease the diameter of the vascular lumen, and
(c) intrinsic changes in the vascular smooth muscle which could result in an enhanced sensitivity to hormones or neurotransmitters.
With respect to the first possibility, a review of the literature has resulted in
a general consensus that there is a tendency for diminished sympathetic nervous
system activity in established hypertension (30,31). This is also true for the SHR
model (26,27), Except for the clinical studies of laragh ~!.::!_:cited above (10).
there is little evidence that the circulating levels cf angiotensin II are elev<Jted.
Recently, Sh iono and Sokabe (28) reported that the renin-angiotensin system was
depressed in the SHR, and it was suggested that this represents a compensatory
mechanism to decrease the blood pressure.
Folkow and his colleagues (32) have presented evidence that adaptive structural
changes within the vasculature are responsible for the maintenance of an elevoted
resistance in established hypertension. These investigators proposed that hypertrophy of the smooth muscle in response to elevated arterial pressures results in an
encroachment of the vascular wall on the lumen of the vessel. Therefore, the
vessel lumen wo:;!d be narrowed in spite of maximum relaxation of the surrounding
smooth muscle. Also, a given shortening of the smooth muscle would lead to an
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exaggerated reduction in the diameter of the lumen in response to normal concentrations of vaso<1ctive agents. Other studies, though, have demonstrated that spirally
cut hypertensive v~ssels exhibit this same enhanced responsiveness (33,34). This
would indicated that simple encroachment into the vascular lumen, alone, would
be an imufficient explanation for the apparent increase in vascular reactivity.
Numerous.!:::_ vivo studies have been reported which support the idea that vessels from hypertensive patients and animal models are highly excitable in the presence of normal plasma concentrations of agents which induce vascular contraction.
Doyle~~ (35) and Daly and Duff (36) found that the hand and forearem vessels

were supersensitive to intra-arterial injections of norepinephrine.

Using hind

limb perfusion techniques in the New Zealand genetically hypertensive rat, Laverty
(37) found an enhanced reactivity to norepinephrine and McGregor and Smirk (33)
made similar observations in the perfused splanchnic bed of the same modei.
When the hind I imb perfusion technique was applied to the SHR, Lois .:,t ~1.
(39) observed that the response to sympathetic stimulation was unaltered, but the
sensitivity of the systemic injection of norepinephrine was enhanced. This was
interpreted J·o mean that there was a compensatory decrease in the amount of norepinephrine released at the adrenergic nerved terminals. Perhaps a more revealing
aspolct of this study was the observation thqt bilateral sympathectomy of the hindqumter vasculaJ·ure resulted in a pronounced decline in the vascular resistance in
the normotensive control, but the vessels of l·he SHR remained ·Constricted. This
persistence of an elevated resistance in the absence of neurogenic influences suggesl·ed that neither excessive sympathetic stimulation nor supersensitivity can completely explain the maintenance of the hypertwsive state.
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The use of ~ ·~itro methods to study the contractile characterists of hypertensive
and normotensive vessels has resulted in conflicting and confusing data.
.:_t

c:J.

Okamoto

(34) reported that the sensivity of the SHR VC/Sculature to norepinephrine was

significantly enhanced over that of the normotensive control, whereas, Clineschmidt
and coworkers (40) were unable to detect any changes in sensitivity to !·he same
agent.

Spector:! ~· (41) and Shibata':.! ~. (42) found that aortic strips from the

SHR were much less sensitive to the effects of norepinephrine, potassium, serotonin,
angiotensin II, and barium.

Similarly, Levy (43) has shown that the contractile

response of SHR aortic strips to PGFz:i. was significantly decreased. An alternative

I:• vitro

method to examine WJScular reactivity was reported by Cohen and Berkowitz

(44), in which the abilily of vasodilators to relax serotonin-induced contractions in

-~

\

SHR aortic strips was studied. It was shown in their studies that the hypertensive
aorta was resistant to the relaxant effects of isoproterenol, nitrogl;·cerin, adenosine,
and dibutryrl eye! ic AMP.
In summary, it appears that the

~

vitro experiments have not demonstrated the

hypersensitivity to vasoactive agents that is seen in the ~ vivo experiments. The
decreased sensitivity of the isolated hypertensive vessels is an enigma and how this
obsarvation is related to actual in vivo conditions remains to be determined.
Sjc!ic Nucl~otides, Vascular Tone, and Hypertension
The development of the concepts regarding intracellular m'Jdiators of hormonal
and neurohormonal messages has been one of the most significant advances in
physiology and pharmacology in recent years •. First described in 1957 by Rail,
Sutherland, and Berthet (45), cyclic 3',5'-adenosinc monophosphate (cAMP) was
found to <Jccurnulate in the particulate fractions of liver homogenates which had
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been exposed to epinephrine. cAMP was observed to stimulate glycogen breakdown
by ocl'ivating soluble cytoplasmic enzymes, but epinephrine was inactive in the
stimulations of these enzymes directly. It was proposed, therefore, that the glyco·genolytic response of epinephrine in the hepatocyte was mediated via cAMP.
Based on these. original studies, this concept of intracellular messengers has been
extensively studied and cAMP has been implicated as a mediator of the actions of
many hormones (46) and neuroh·ansmitters (47). The basic components of I he cAMP
second messenger system ore shown below.

hormone

!

[--------~----r-e_c_e--ptor

adenyl eye lose

ATP

-·-»

cAMP

---'~>

t

PDE

protein kinase

5'-AMP

---·»

altered cell function

As a result of the hormone-receptor interaction, a plasma membrane enzyme,
adenyl cyclase, catalyzes the conversion of intracellular ATP to cAMP. An increase in the formation of cAMP ieads in tum to the c•clivation of specific protein
kineses (phosphotransferases) which catalyze the phosphorylation of intracellular
cornponenl·s to affect cell function.
The effects of cAMP are terminated by its rapid hydrolysis to 5'-AMP. This
reaction is catalyzed by a specific cyclic nucleotide phosphodiesterase (PDE) which
is found in both the cytosol and membrane fractions of most cells.

11

In the early l'?70's the existence of another cyclic nucleotide second messenger
was discovered to mediate the effects of acetylcholine on the myocardium (48).
This nucleotide, 3' ,5'-cyclic go;anosine monophosphate (cGMP), is similarly formed
by the action of a guanylate cyclase, and .its actions are terminated by a specific
soluble phosphodiesterase. A number of hormones have been shown to increase
cGMP levels in a number of cell types, but in most cases the physiological significance is not clearly understood.

In some instances, the physiological response

has been found to be opposite that produced by agents which tend to increase cAMP
levels, and this has led Goldberg and coworkers (49) to postulate that cAMP and
cGMP have antagonistic regulatory roles in cell function.
The role of cyclic nucleotides in cardiovascular function hils been extensively
studied, and it is currently accepted that many agents which modify the contractility
of cardiac and vascular smooth muscles do so by altering the intracellular concentrations of either cAMP or cGMP.
For example, beta- adrenergic agonists, glucagon and histamine have been
shown to increase the levels of cAMP in myocardial tissues concomitant with an
increase in the force of contraction (50,51 ,52). Additional evidence has been
obtained when the direct exposure of isolated cardiac tissues to cAMP has resuhed
in a positive inotropic effect which is independent of neurogenic influences (53,54).
Recently, George et

~.

(48,55) reported an increase in the level of myocardial

cGMP in rcspome to acetylcholine just prior to a decrease in contractile tension.
Based on these experimeni·s, it is now fairly certain that muscarinic and vagal influences on cardiac contractility are mediated via changes in cGMP.
With respect to vascular smooth muscle, there is now a growing body of evi-
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dence which suggests a role for eye! ic nucleotides in the regulation of vascular
tone. Triner :_!

~.

(56) found that isoproterenol, epinephrine, and norepinephrine

increased cAMP levels in the isolated rat aorta, and in the presence of alphaadrenergic antagonists each compound had a relaxant effect. In addition, inhibition
of cAMP degradation by the phosphodiesterase antagonist, theophylline, increased
the tissue lev<"ls of cAMP and induced relaxation of the vessel.
Andersson (57) examined the effects of other vasa-relaxants, such as hydralazine,
nitroglycerin, diazoxide, and papaverine in bovine mesenteric arteries.

In each

case, relaxation wos accompanied by a prior increose in cAMP. Sprague (58) and
Nagai and Sprague (59) measured the effects of anesthetic agents on cAMP and
vascular smooth muscle tone. lsoflurane and halothane inhibited the phenylephrine··
induced contraction and it was observed that the degree of vascular r.elaxation
and the rise in the tissue levels of cAMP were correlated. !n other experiments by
Triner and coworkers (60) cAMP was found to relax norepinephrine-contracl'ed
aortas. Cohen and Berkowitz described similar results for the serotonin-contracted
rat aorta (44), and Levy (61) showed that dibutyryl cAMP could antagonize the
contractile effect of PGE on the rabbit aorta.
2
There has been very little study of cGMP metabolism and its relationship to
vascular smool'h muscle function.

However, Sutherland and coworkers (62) de-

monstrated that the histamine··induced contraction of isolated pig coronary arteries
was associated with a rise in cGMP.

Dunham :_!

':!.

(63) found that constriction

of i·he canine saphenous and bovine digital vein strips by PGF2 <X was associated
with a comcomitant rise in, cG/v\P levels, but Cohen and Berkowitz found that
cGMP had a direct relaxant effect on the isolated rat aorta (44).
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Based on th~. studies regarding the proposed relationship between cyclic
nucleotides anthoscular. smooth muscle tone, Amer (64) hypothesized that the high
contractile toneumd elevated vascular resistance in the hypertensive vessel could
be the result of,a!Onormally low levels of cAMP in the smooth muscle. This hypo·thesis was confim0d when cAMP levels were measured in the aorta of several
hypertensive moli.lels, including the SHR, stress, DOCA, ar.d neurogenic hypertensive rats (64,$15,66).

Because of the enhanced vascular tone in the hypertensive

animals, this ob,;~nvation tended to validate previous studies that there was an inverse relationshi;p; between the degree of vascular contraction and the levels of
cAMP.
The decrease in aortic cAMP appeared to result from a concomitant increase
in the specific activity of a high affinity form of cAMP phosphodies:·erme and a
reduclion in the sensitivity of adenyl cyclase to beta-adrenergic agonis,fs when
assayed in cell-free systems. Gucmyiate cyclase activity was also enhanced in the
hypertensive aorta and this correlated with an increase in the intracellular cGMP
concentration (65,66). As discussed above, the evidence that cGMP is associated
with vascular smooth muscle function is meager, therefore, this observation provided
a unique forrn of evidence that this cyclic nucleotide could be a factor in the
mediaHon of vasoconstrictive mechanisms,
In a similar study of cAMP metabolism alone, Ramanathan and Shibata (67)
confirmed the low cAMP levels in the vascular tissues of the SHR and also found
that this abnormality

WCIS

present in the young prehypertensive SHR.

In marked

contrast to those studies reported by Amer (64,65), it was demonstrated by these
investigators that the hypertensive blood vesse.ls had a lower cAMP PDE activity
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than the normotensive controls. Their data also showed that the basal adenyl cyclase
activity was significantly lower in the SHR aorta, but 5imilar activities were observed in the presence of glucagon, epinephrine, and NaF.
In spite of these differences in the specific enzymatic alterations which appear
to be related to the changes in cAMP metabolism, these studies have given additional merit to the theory that cAMP and perhaps cGMP could be important
factors in the regulation of vascular contractile tone. These data, therefore, could
provide the answer to the quest for the biochemical lesion which is associated with
the alteration of vascular re<Jctivity in the hypertensive vasculahJre.
State.r~ent of Rese~rch Objective

Because of the serious questions regarding the relative impor!·ance of the adenyl
cyclase and phosphodiesterase activities to the changes in cAMP metabo!isr.1 in
the Vtlsctdar tissue of the SHR, it was decided that experiC"Jents should be designed
to resolve t·hese differences.

In addition, the second obje~tive of this study was

to investigate the kinetic properties of these enzymes in considerable detail.

It

wc;s expected that the information obtained from these characterization experiments
would furthec our understanding ')T the mechanism responsible for their altered
kinetic beh<•vior in the hypertensive vessel.
The third objective to be explored was an appraisal of rhe correlation between
the level of blood pressure in the hypertensive model and the relative changes in
the vmcular smeoih muscle concentrations of cAMP and cGMP.. The results oF
thes·e experiments allowed the distinction to be made between changes in cyclic
nucleotide metabolism which occurred prior to or secondary to the development of
hypertensive state.

METHODS

Thomcic oortos 1 weighing approximately 50 mg and about 3 em in length,
were dissected free of the adventia and placed in an ice cold medium of 0. 32M
sucrose and 10 mM Tris-HCI (pH 7.5). The vesseL was bisected longitudinally
and weighed on

CJ

Smith-Roller tissue balance. The tissue was then homogenized

in .5 volume> of the medium with a Brinkman Polytron (10 sec., dial setting .5) and
the cwde homogenate was centrifuged at 4000 x g for 15 minutes in a Sorvall RC-2
refrigerated centrifuge (SM 24 Rotor}, The supernatant was deccmted and used
Jireciiy for assay.
Prepa!:::!~on of Tissues for cAMP/cGMP Assay

Samples of the thoracic aorta>, weighing approximately 50 mg 1 were rapidly
rer.1oved frotn the animal and frozen by means of "Wollenberger" tongs (68) which
hod been previously chi lied in a mixture of ethanol and dry ice (-80° Q. The
frozen tissues were homogenized in 1.0 m! of 5% trichloroacetic <Jcid (TCA) with
t·he Brinkman Polytrcn anc centrifuged at 4° C in o Sorvall RC-2 centrifuge (SM 24
Rotor) at 8000 x Q for 10 minutes. The supernatant was decanted 1 end the TCA
was extrocted by adriinu 4.0 ml of woter-saturated ether 1 vortexir.g, and Glspiroting
the ether layer. This procedure was repeated .5 times and the residual ether was
removed by heating the tubes to 60°( in o hot \lo'ater bath fer 3 minutes. The samples
were !yc.philized (Virtis Co., Model 10-117) and immediotely "econsituted in
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0.5 ml of 50 mM Tris-HCI and 4 mM EDTA (pH 7.5). The samples were either assayed
at this time or frozen and stored overnight at -20°C.
The TCA precipitate was dissolved in 0.5 N NaOH and assayed for the protein
content by the method of Lowry (69).

Thorc:cic aor~as were removed as described above and homogenized with a Dounce
oll--gla3s homogenizer in 10 volumes of ice--cold 40 mM Tris-HCI, pH 7.4. A
washed enzyme preparation was made according to the procedure of Ramanathan and
Shibato (67) by centrifuging lhe crude homogenate at 2200 x g for 15 minutes (Sorvall
RC-2, SM 24 Rotor). The pellet was taken up in the tris buffer and the centrifugation

--j
1

was repeated two additional times. The final pellet was resusper.ded in the buffer
used in _the adenyl cyclase assay (fee adenyl cyclase asscJy p!·cccd,Jre for ~he com·-

position of this buffer).

Phosphodiesterase (PDE) activity was determined according to the method of Amer
(64) which was a modification of the procedure orginally described by Thompson
and Appleman (70). This assay is applicable for the assay of either cJ\MP or cGMP

POE activit/. The procedure is based on the conversion of tritialed cyclic nucleo··
tides to the corresponding nucleoside by the sequential action of PDE and snake
venorn nuc I ectid,:!se.

3

PDE
H-cyclic nucleotide

_ ___,,. 3 H-5'-·nuc leotide
!

~

1'

nuc!eotidase

.)H-nucleoside + Pi
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The negatively charged cyclic nucleotide and 5' derivative are separated from the
nucleoside by binding the nucleotides to an anion exchange resin and the nucleoside
is memured by liquid scintillation techniques. The following is a complete description
6
of the procedure with cAMP as f·he substrate at a concentration of 10- M. The assay
of cGMP PDE is identical.
I)

Set up on ice the appropriate number of disposable microtest tubes (Bio Rod
I. 5 ml) and add the reagents in the following order:
0. I ml 160 mM Tris, 40 mM MgS0 4, pH 7.5
0.05 ml enzyme
0.15 ml water

1

-~-lj

2)

Preincubate for 3 minutes at 30°C.

3)

Initiate the reaction by adding 0. 10 ml cAMP (4. 0;1M) containing 0. I
3
microcuries of H-cAMP. The final volume is 0. 40 mi.

4)

Incubate for the desired time at 30°C, usually 10·- 15 min, depending upon
the Iinearity of the reaction.

5)

Terminate the reaction by immersing the tubes in boiling water for 90 sec.
Timing is important for excessive exposure to high temperatures increases the
bland value.

6)

R;;turn the tubes to the 30° water bath for 5 min.

7)

Add 0.10 ml of snake venom nucleotidase (~~rotal~~.::!.':_ox, I mg/miL vortex,
and incubaf·e for an additional 10 min at 30°.

8)

At the er.d of the incubation period, transfer the tubes. to an ice bath and
add 0.~0 ml of a 1:2 slurry of Bio Rod AGI-X2 anion exchange resin.

9)
10)

Vortex and equilibrate at 4°C for 15 min.
At the end of the equilibration time, vortex again, and centrifuge at 8000
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x §1. for 2 min using the Brinkman Model 3200 Microcentrifuge.
11)

Transfer 0.20 ml of the supernatant to 5 ml of a dioxane-based liquid
scintillation cocktail and count to 2% statistical precision on the tritium
channel (Beckman CPM 100 Liquid Scintillation Counter).

Calculation of the Results:

v

=

measured cpm
total cpm

X

picornoles substrate

incubation time

X

protein (mg/ml)

x 20

Additiona I t'lotes:
1)

The total cpm is determined by adding water (0.50 ml) instead of the anion
exchange resin, vorl·exing, and taking the 0.20 rnl aliquot for counting.

2)

Polypropylene, 7-ml, scintillation vials were obtc,ined from New England
Nuclear Corp. The minivial was adapted to the CPM 100 counter by
placing the vials in 30-rnl Beckman Poly-Q Vials.

Reagents:

J)

Tris HCI, 160 mM, containing 40 mM MgS0 , pH 7.5.
4

2)

C~:otalus atrox snake venom (Sigma Chern. Co.) is made up to a final

concentration of 1 mg/ml in 10 mM Tris-·HC!, pH 7.5. The enzyme solution
is stable for about one week at 4°C.
3)

3

H-·cAMP is prepared by diluting !·he stock solution (Amersharn/Searle Corp.,

30 curies/mM) 20 times with 50% ethanol/water. The diluted s!·ock is
stored at ·-20°C. The working solution is prepared:by adding 0.010 ml of the
diluted stock to 2 ml of cold cAMP (4jJM). This solution should be mode up
daily and the unused portion discarded.
4)

The onion exchange resin is prepared by wasing the Bio Rc1d AG 1-X2 resin

i9

(CI··, 200-400 mesh) with 5 ·;olumes of 0.5 N NaOH, 5 volumes of 0.5 N
HCI, cmd repeatedly with distilled water until the pH of the slurry is five.
This whole procedure in performed in a large beaker by adding the solvent's
to the resin, stirring, ollowing the resin to settle, and decanting. The final
1:2 slurry is made by allowing the resin to settle and adding two volumes of
40% methanol.
5)

The liquid scintillation cocktail consists of 7.5 g PPO, 0.376 g POPOP,
and 125 g napthalene per liter of scintillation grade p-dioxane.

!-de,::'r!_ Cy~~~~!-ssay
Adenyl cyclase activity was assayed according to the ~ethod of Amer (64). The
incubation mixture conl·ained 0.5pmoles of ATP, lO}Jmoles phosphoenolpyruvate

-~~-I
1

(PEP), 32.5jJg of pyruvate kinase, 1}Jmo!e of theophylline, 2.75)Jmoles of KCI.,
7.5pmoies of lvlgS04 , _c;nd 20tJrnoles of Tris-HCI, pH 7.4, in a total volume of
0.505 mi. The cAMP formcd during the reaction was purified on Bio Rod AG 1-X2
anion exchr,ngc columns (formate) as described by Murad<:_!~!· (71). The following
is a description of the prcro-:ol:

J)

T0 microtest tubes (Bio Rod 1.5 ml) on lee, add the reagents in the following
c-rder:

buffer
AT?

Pi:P
pyruvate kinase
2)

0.200
0.100
0. 100
0.005

ml
ml
ml
ml

Preincubote at 3j"J( for 3 min and initiate the reocticn by the addition of
0.100 of the enzyme suspension.

Boiled enzyme is used

OS

the blank.

3)

Incubate for 20 min and terminate the reaction by boiling for 3 min,

4)

Centrifuge at 8000 x g for 2 min and transfer 0. 400 ml i·o the AG 1-X2
.~

formate co.lumns (4 em x 0. 4 mm),
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5)

Wash the ool'umns with 5 ml of distilled woter and collect the cAMP by
elution wafflln 5 ml of 2 N formic acid.

6)

Lyophiliz«ll fine eluate and resuspend in 0.200 ml of 50 mM Tris, containing

4 mM EDT-A, pH 7.5.
7)

Assay ofl1l .. '!l50 aliquot by the cAMP protein binding assay. Specific activity
is then .~..-pressed as pmoles of cAMP formed/min/mg protein.

Additional Notes.:
I)

The AGI-X2 formate columns were made by pouring a slurry into a Pasteur
pipetted which had been previously fitted with a glass wool plug. A small
glass funnel was attached to the columns by way of a short piece of rubber
tubing to ·G!d as a reservoir.

2)

Recovery of cAMP from the formate columns was mon itered by the use of
an internal standard and was usually in the range of 50-55%.

Reagents:
I)

Pyruvate kinase was obtained as an ammonium sulfate suspension from Sigma
Chemical Co. The concentration is 4 mg protein/mi.
Tris HCI
Theophylline
KCI
MgS0
4

Store a 4°C.

2)

Buffer

4.84 g/L
360 mg/L
410 mg/L
3.70 g/L

3)

ATP (Sigma Chemical Co.)·· 5.0 mg in I .6 ml buffer.

4)

PEP (Sigma Chemical Co.)- 25 mg in 0.8 ml buffer, Keep frozen,

Keep frozen.

The ob;lil'/ of cotecholornines to stimulate adenyl cyclase in the intact aorta was
assayed ns ce,cribed by Cohen and Berkowitz (72).

Intact aortas were placed,

without tension, in a 50-ml isolated tissue bath of the following composition (mM):
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dextrose, 10; om.! NaHC0 , 24.8. The bath was double chambered and connected
3
to a circulating, constant temperature pump CNill Corp.). The vessels were equilibrated with 95% 02 and 5% C0 at 3~ For 60 minutes prior to the exposure to the
2
drugs. After exposure to the drugs For 30 minutes the tissues were quickly removed
and homogenized in 1. 0 ml of 5% TCA with a Brinkmon Polytron. The homogenized
tissue was processed as previously described for the assay of cAMP. The results
were expressed as pmoles of cAMP per mg protein.
cAMP Assay Procedure
The assay of cAMP is a modification (73) of the method reported by Gilman (74)
and is based on the competition of cAMP in the sample and

3

H-cAMP for a highly

3
specific binding protein. The amount of H-cAMP bound is inversely related to
the quantity of cAMP in the sample. 'vVith the use of a standard curve, the unknown cAMP conce>ntration can then be determined. The <JSS<ly kH was ol:.tained
from !he Amersham/Searle Corp. and the procedure is specific for cAMP in the
range of 0.2 to 16 pmoles per incubation tube. The following is a complete description
of the ass.:Jy protocol:
1)

Set up on ice 14 disposable microtest tubes for the blanks and cAMP standards
fallowed by the pppropriate number of tubes for the unknowns in duplicate.

2)

Tubes one and two are used for the assay blank. To these tubes add 0. i50
ml of buffer reagent 1.

3)

Pipetf'e 0.05 ml of buffer reagent 1 into tubes three and four which are used
to determine the binding in the absence of unlabeled cAMP.

4)

To tubes five though 14 add 0.05 ml of the standards (1,2,4,8, & !6 pmoles

per os:>.Jy tube).
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5)

Add 0.05 m! of the unknown samples to the remaining tubes in duplicate.

6)

Add 0.05 ml of the

7)

Pipette 0. 100 ml of the binding protein reagent into all tubes except one

3

H-cAMP solution to every tube.

and two and vortex.
8)

Place the ice bath containing the tubes in a 4° cold room for two ho\Jrs.

9)

At the end of the equilibration period, add 0. 10 ml of the charcoal reagent
to all tubes and vortex. Centrifuge the tubes immediately at 8000 x

g for

two min. Do not add the charcaa I reagent to more tubes than can be centrifuged in one batch.
10)

Remove a 0.20 ml aliguot from each tube after centrifuging each batch and
add to 5 ml of a dioxane based liguid scintillation cocktail (see PDE assay).
Count to 2% statistical precision using the Beckrnon CP;\A 100 liquid
Scintiilation Counter.

Calculation of the Results:
1)

Average the cpm for all tubes and substract the blank.

2)

Divide the net cpm bound in the absence of unlabeled cAMP (Co) by the
net cpm in the presence of unlabeled cAMP (Cx}.

3}
u

Plot Co/Cx against pmoles of standard cAMP on linear graph paper. A
straight line should be obtained with an intercept of 1.0 on the ordinate.

4)

From the Co/Cx for the unknowns, read the number of pmol<ls present in
the sample.

Reagents:
All of the reagents were obtained in lyophilized form from the Amersham/Searle
and were reconstituted according to the instructions received wit-h the assay kit.
Except for the binding protein, all of the reagents could be thawed and frozen
repeatedly for the life of the kit.

23

1)

Buffer Reagent 1- 50 mM Tris, 4 mM EDTA, pH 7.5.

2)

Binding protein reagent- c1dd 15 ml of distilled water, gently swirl, and
aliquot into 1.0 ml fractions and freeze.

3)

Charcoal Reagent- add 20 ml of distilled water, stir, and keep frozen.

3
4)

5)

.
H-cAMP .. add 10 ml of distilled water and keep frozen.

cAMP Standards- add 5 rnl of distilled wal·er and mix.

Each 0.05 ml of

this solution will yield 16 pmoles to each assay tube. The remaining four
standards a~e prepared by serial dilution by adding 0.5 ml of the standard
to 0.5 ml of buffer reagent 1. After throughly mixing, transfer 0.5 rnl of
this dilution to 0. 5 rnl of buffer reagent 1. This procedure is repeated two
additional times, resulting in cAMP standards of 16,8,4,2, and 1 pmoles
per 0. 05 ml respectively. All of the standards should be kept frozen.

I

cG.'v\P Assay Procedur=.
The radioimmunoassay (RIA) of cGMP is based on the compel'ition of cGMP and
3 H-cGMP for an nntibody which has a high specificity and affinity for i·he cyclic
nucleotide. The amount of 3 H-cGMP bound to the antisera is inversely proportional
to the quantity of cGMP present in the assay mix. The cGMP bound to the antibody is s•;parated from the free form by precipitation with ammonium sulfate, redissolved in water, and counted by liquic;l scintillation. The reagents for the assay
were obtained from the Amershom/Searle Corp. and the procedure is sensitive for
cGMP in the range of 0.5 to 8 pmoles per incubation tube. The following is a
complete description of the assay procedure:

1)

Set up on ice 14 disposable test tubes for the blanks and cGMP ;l·andards
followed by the apprcprial'e number of tubes for the unknowns in duplicate.
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2)

Pipette 0.00 ml 3 H-cGMP into each assay tube.

3)

Add 0. 10 mfi of the buffer reagent into tubes one and two. These tubes are
used to determine the binding in the ubsence of unlabeled cGMP (Co},

4)

To tube.s J:..J2, add 0.10 ml of the cGMP standards in duplicate (0.5, 1,2,4,

8 pmoles per tube).

5)

Add 0.10 ml of the blank reagent to tubes 13 and 14. These tubes are used
to determine the assay blank.

6)

Add 0.10 ml of the unknown samples to i·he remaining tubes in duplical·e.

7)

Add 0.05 ml of the anl"isera to each tube and vortex.

8)

Place the ice bath contclining the tubes in a 4° cold room for 90 min.

9)

At the end of the equilibration period, add l.O ml of ice cold (NH 4)zS0
4
to as rnany tubes as can be centrifuged in ane batch. Vortex, return to
the ice br.1th, and aile~/ them to stand for 5 min.

10)

Centrifuge at 8000 x £!;for 2 min and aspirate the supernc1tant into a filtration
flask.

11)

When all of the tubes have been centrifug•;d and mpirated, dissolve the precipitate in 1. l ml of distilled water.

12)

Remove a I .0 ml aliquot and add to 5 ml of the dioxane-based liquid
scintillation cocktail and count to 2% statisticol precision.

Calculation of the Res>Jits:
I)

Average the cpm for all the tubes and subtract the blank.

2)

Divid the net cpm bound in the absence of unlabekd cGMP (Co) by the
net cpm in the presence of unlabeled cGMP (Cx),

3)

Pl·~t Co/Cx against f·ha pmoles of cGiviP standard on linear graph paper.
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4)

From the Co/Cx for the unknowns, read the number of pmoles present in the
sample.

Reagents:
All of the reagents were obtained in lyophilized form from the Amersham/Searle
Corp. and reconstituted according to the instructions received with the assay kit.
After reconstitution, all of the reagents should be stored frozen and can be thowed
and reftozen repeatedly throughout the life of the kit.
l)

Buffer Reagent- 50 mM Tris, 4 mM EDTA, pH 7.5.

2)

Antiserum- add 7.5 ml of distilled water and gently swirl.

3)

3

H-cGMP- dissolve in 10 ml of distilled water.

4)

Blank Reagent- dissolve in 2 ml of distilled water.

5)

Ammonium sulfate- transfer the salt to a beaker and add 150 ml of distilled
water.

6)

cGMP Standards- add 5 ml of distilled water and mix. This solution gives
8 pmoles per 0.100 rnl. The remaining standards (4,2,1, 0.5 per 0.10 ml)
are prepared by serial dilution with the buffer reagent.

Prctc,in Determination
Total prot.ein was measured by the method of lowry (69) in which a colored
complex is formed

du·~

to the interaction between tyrosine and tryptophnn residues

and the alkaline-phenol reagent-. A standard solution of bovine serum albumin (BSA)
was prepared and a standard curve from 10-60 pg was plotted. The unknown protein
is then dehmnined from the standard curve. The details are as follows:
l)

Dilute duplicate samples of the stock BSA solution, 0.05, 0. 10, 0. 15, 0.20,
0.25, and 0.30 ml to 1.5 ml with distilled water. likewise, dilute the
protein samples (usually 0.05 ml) to the same total volume.

2)

Add 1.0 ml of reagent C, vortex, and incubate for 10 min at room temperalwe.
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3}

Add 0. 10 ml of reagent E while the tubes are being vortexed and incubate
an additional 30 min.

4}

Determine the OD at 750 nm and 0.5 mm slit width (Beckman ACTA II}.
Construct a standard curve from 10-60 }Jg of BSA and determine the ug of ·
protein present in the sample directly from th0 curve.

Reagents:
1}

BSA, 200 pg/mi in disti!led water, Store at 40 and discard after 30 drJys.

2)

Reagent A- 2% NaC0

3}

CuS0 4 - 1% in distilled water. Siore at room temperature.

4)

Na··K Tartrate- 2% in distilled water, Store at room l·emperature,

5)

Reagent C- mix CuSO and Na-K Tartrate 1:1 and dilute 50 Hmes with
4

3

in 0. 1 M NaOH,

Store at room temperature.

reagent A. Make this solution fresh each day.
6)

Reagent E- dilute Folin-Cie<oalteau phenol reagent 1:1 wi\·h distill,;d water.
Make this solutioo1 f•esh each day.

Anima Is
Spontaneously hypertensive rats (SHR), of the original Wistar-Kyoto strain developed by Okamoto and Aoki (25} were used in these experiments. The original
breeding s·tock was obtained from Dr. J. V. Levy of the Pacific Medico! Center,

Sm1 Francisco, Ca. Our breeding colony was developed and maintained by ftJii
brother-sister mating in our own animal facility.

Siblings were mated at approximately

12 weeks of age by placing 3 males and 3 females in a breeding cage. The breeding
animals were checked daily for births and if a birth had occurred, the mother and
her litter were separated from the ethers.

in mo;t cas~; the litter size ranged from

5-9 and the mother was all0wed lo <Jive birth to only three liters. The litters were
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weaned at 21 days after birth.
Normotensive Wister-Kyoto rats 0NKY), obtained from the same source, were
used as the controls. Mating procedures for the WKY were the same as described
for the SHR, except that breeding was at random rather than brot·her-sister.
Both strains of animi:tls were housed in th13 same animal room which was maintained at 22--26°( under a 12 hour light-dark cycle. Rut chow (Simonsen Lab.,
Gilroy, Ca.) and tap woter were given ad _libitum. The bedding material had a
wood fiber base and was obtained from Pharmcal. 1nc., Kansas City, Mo. Only
male animals were used in the experiments,
Blood Pressure Determination

The indirect systolic blood pressure of the tail artery was measured using a
Norco Biosystems Sphygmomanometer (P-300) without anes!·hesia in an isolat·ed,
quiet room, The rats were prewarmed in a holding chamber (32-33°C) for 1015 minutes prior to being transferred to the Norco Bio-System restraining cage and
warming plate {dial setting 6). After the animal had become equilibrated to the
restraining device {usually about 5 min), three recordings, takenat approximately
one minute intervals wNe taken. The final recorded blood pressure was the mean
of the three measurements. The blood pressures of all animals used in the experiment·s were documented on the day prior to sacrifice,
Ora I .;ntihyp:r..ten>i''':...I~empr
The SHR 1·eceiving chronic antihypertensive treatment were housed in groups
of five and each group received the .appropriate agent via their drinking water. The
drugs were dissolv,,o in tap wat·er at 1·he following concentrations:
reserpine base (CIBA)

2.5 mg/L
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chlorothiazide, sodium (MSD)
clonidine HCI (Boehringer Sohn)
hydralazine HCI (CIBA)
propanoic! HCI (Sigma)

1000
5
JOO
600

mg/L
mg/L
mg/L
mg/L

Under these conditions of five rats per cage, the water consumption was estimated
to be approximately 20 ml per rat per 24 hours. Based on this value, J·he actual
dosage (mg/kg) could be approximated.
reserpine
chlorothiazide
clonidine
hydralazine
rropanolol

0.05
20.0
0.01
/

2.0

12.0

The control SHR received only tap water throughout the treatment period. Th.,re
was no difference in water consumption or body weights for the control and tre<Jted
groups. Blood pressures were determined prior to the initiation of the therapy and
at weekly interva Is thereatfer.
~~atistical Analysis

All mean values were compared by the Student's!:" test (two tailed), and
diffecences with a~ value of 0.05 or less were considered significant.
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Figure 1 - Adenyl Cyclase Assay --Time Dependency
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Figure 2- cAMP Phosphodiesterase Assay-- Protein and Time Dependency.
Substrate concentration was 0. 001 mM.
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RESULTS

Propert1es of the SHR Colony
Six week old SHR exhibited normal blood pressures when compared to agematched WKY controls, but as early as 8 weeks of age, the blood pressures were
significantly higher in the SHR and reached a maximum at approximately 12-16
weeks of age (Fig. 3).

No difference in body we.ight could be detected up

to 12 weeks (not shown), a Ithough there are reports in the Iiterature that the
SHR is smaller at older ages (75). At bath the prehypertensive age (6 weeks)

·-1

and at 12 weeks the ratio of total heart weight to body weight was significantly
elevated over the normotensive control, whereas changes in spleen, kidney, and
adrenal ratios were not apparent (Table 1).
Phosphodiesterase (PDE) Kinetics
The possibility that PDE activity has a primary role in the changes in cAMP
metabolism observed in the vascular tissues of hypertensive animals (64,67) is
controversial. Therefore, it was essential to establish the role of PDE in our own
animals in an attempt to resolve this conflict in the literature.

It also appeared

necessary to further investigate the properties of this enzyme in the vascu.lar
tissues of hypertensive and normotensive rat·s.
Subcellular Distribution When measured at low substrate concentration to detect
the activity of the high affinity form of PDE (76), 67% of the PDE activity was
associated with the 100,000 x

g supernatant (Fig. 4) and the specific activity

in this fraction was approximately 1.5 times that of the other fractions (Fig.5).

Figure 3- Age Dependent Changes in the Systolic Blood Pressure.
Open circles- SHR, closed circles- WKY
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Table I - Organ /Body Weight Ratios in the SHR and WKY Normotensive Rats

1

12 Weeks

6 Weeks
Organ
SHR

(n)

-2

WKY

(n)

SHR

WKY

(n)

3

(n)

Heart

672 . 1 ± 19. 8 ( 11 )

570.6 ±24.5 (8)

422.4 ±5.9 (41)

Kidney

934.5 ± 19.0 (8)

998.8 ± 32.6 (6)

391.6 ±9.2 (31)

451.5 ± 26.6 (11)

Spleen

639.6 ± 42.2 (8)

670.5 ±41.3 (6)

245.0± 8.2 (J 1)

240.7 ± 11.1 (7)

Adrenal

12.2±3.1 (4)

12.2 ± 1.7 (4)

8.0±0.5(24)

8.3 ± 0.8 (11)

359.1± 8.5(15)

1
Values are expressed as mg per 100 mg body wt. ± SEM.
2
3

Significantly different from WKY control,
Significantly different from WKY

~ <

control,~

<

0. OJ.
0.001.

w

o--
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Figure 4- Subcellular fractionation of cAMP phosphodiesterase activity in the rat
aorta. Substrate concentration was 0.001 mM. HOM= homogenate,
NF =nuclear fraction (600 x g x TO min), MITO =mitochondrial fraction
(10,000 x g x 15 min), SUP =supernatant (100,000 x g x 60 min), MIC =
rnicrosomes(TOO,OOO x g x 60 min).
(n = 2)
-
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Figure 5- Subcellular fractionation of cAMP phosphodiesterase activity in the rat
aorta. Specific activity is expressed as pmoles cAMP hydrolyzed/min/
mg prole in. Substrate concentration was 0. 001 mM. For explanation
of symbols see Fig. 4. (n = 2)
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pH Dependent Activity Figure 6 illustrates the activity of cAMP PDE in the
100,000 x Q supernatant as a function of pH in Tris-HCL buffer containing 10
mM MgS04. The specific activity was measured at the pH values of 7.0, 7. 3,
7.5, 7.8, and 8.0 and the maximum activity was observed at pH 7.5 and was
sharply attenuated ot the higher or lower pH values. The observed pH optimum
is simi lor to those reported for uterine smooth muscle (77), bovine heart and
brain (78), and rat brain (79), but contrasts with an optimum of 9 in the rabbit
aorta (80).

It is not clear as to why the pH dependent activity of the rabbit

aorta is different from the rat aorta, except that the former was determined
using a partially purified enzyme.

cAMP POE derived from the SHR and WKY

aortas exhibited virtually identical pH dependent activities.
Magnesium Dependent Activity Approximately 30% of the maximum activity was
detected in the absence of added magnesium ion (Fig. 7). This residual activity
was presumably due to endogenous Mg+2 in the reagents and tissue samples for it
has been reported that LmM EDTA will abolish this apparent magnesium independent
activity (81). Additional Mg +2 appeared to provide maximal activity for the
enzymcsofboth the SHR and WKY aorta at a concentration of 10 mM; excess
magnesium up to 20 mM did not further enhance the activity. These results are
comparable to those reported for a variety of tissues (82).
Sub:trate Dependant Acti·1it~ The assay of cAMP PDE activity at a substrate
concentration of 10-6M, under optimum conditions for the rat aorta, revealed
significant differences which were dependent upon the source of the enzyme.
The specific activily in the WKY aorta was approximately double that of the
enzyme derived from the SHR (Table II). These data show that the observed low
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Table ll - Cyclic Nucleotide Phosphodiesterase Activity in the Aorta of the SHR and WKY Rats

pmoles hydrolyzed/minute/mg protein± SEM (n)
Animal

Blood Pressure

-cAMP PDE

1

134.6 ± 4.6 (15)

63.5 ± 5.8 (7)

SHR 1_

190. 0 ± 3. 3 (23)

31.5 ± 1.8 (8)

4
SHR- T

140.7 ± 3.7 (4)

40.9 + 8.7 (4)

WKY

cGMP PDE

116.5 ± 10.9 (7)
2
2

78 . 3 ± 7. 9 (8)
55.1 ±6.8 (4)

3

2

1
Anima!s used in this experiment were 12 weeks of age.
2

~

<0.001.

control,~

<0.020.

Significantly different from WKY co:1trol,

3

Significantly different from WKY

4

The treated SHR received 2.5 mg reserpine (base) and 1000 mg chlorothiazide (sodium)/liter in their drinking
water from 6 to 12 weeks of age.

~

o-
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level of cAMP in the aorta of the SHR is not the result of an enhanced rate of
hydrolysis of cAMP to 5'-AMP and confirms a similar report of Ramanathan and
Shibata (67). This differs with the results of Amer and his coworkers (64,65,66),
who observed an increased PDE catalytic rate in the blood.vessels of different
hypertensive rat models, including the SHR.
In an effort to evaluate whether the decrease in PDE activity was substrate
specific, the velocity was determined with u similarly low concentration of cGMP
as the substrate (Table II).

In spite of the increased rate of cGMP hydrolysis

as compared to cAMP, the specific activity from the SHR aorta was significantly
lower than that from the WKY control.
Experiments on the rate of cAMP hydrolysis by POE as a function of substrate
- - j'

concentration, yielded the characteristic nonlinear double rc<miproccJI plot (Fig. 8).
This would suggest that some type of negative cooperativity might be occurring
or that there are multiple enzymes in the supernatant fraction wnich have different kinetfc properties.

It is I ikely that the latter situation is true, since it

has been demonstrated that there are at two distinct forms present in the rat aorta
(64), brain (83), and heart (84), which have differing Michaelis constants of
approximately I x 1o-6M (high affinity form) and lxlo-4M (low affinity form).
Extrapolation of the linear portions of these plots yielded two apparent Km's for
cAMP, or1e of 5. 5 x 10-6M and the other of 5 x J0-4M. Based on the extrpolated plots differences in the apparent Km's for the WKY and SHR enzymes
cannot be distinguished. The maximal velocity of the high affinity form is
greater for the WKY enzyme which supports the experiments described above

48

Figure 8 - The effect of substrate concentration on cAMP phosphodiesterase activity
in the SHR (open circles) and WKY (closed circles) aorta.
The enzyme source was a 4000 x g x 15 min supernatant. (n = 3)
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in which subsah.rnllfring concentrations of substrate were used.
Tissue Specifici'ty To check for the tissue specificity of the abnormal PDE
velocity, the specific activity of t·he low Km enzyme in the cardiac tissue
and the cerebral cortex were everuated. As expecl"ed from the observations
of ·Amer (65) and Ramanathan and Shibato {67), the changes in PDE octivity
was not restricted !o vascular tissue, but was present in the heart {Table Ill).
There was no difference in t·he velocity of the reaction when the enzyme activity
from the cerebral cortex of the SHR and WKY were compared (Table IV).
Relationship of Blood Pressure to PDE Activity Since these experiments were
performed on tissue taken from mature, but severe hypertensive animals, we
conducted experiments to determine if the level of blood pressure will alter PDE
activity. Two approaches were token. The first was to measure the activity

j
1

in the prehypertensive SHR, and the second was to determine the enzyme activity
subsequent to treatment of the SHR with antihypertensive drugs.
At both 6 and 12 weeks of age, cAMP PDE acitvity in the SHR aorta was significantly lower than the respective controls (Table V). Activity decreased with
age in the SHR, but not in the WKY which suggests a relationship between PDE
activity and the development of the hypertensive state. With respect to cGMP
PDE activity, a comparison of the mean values for the two ages in the SHR suggests
a similar t-rend, but the values were not statistically significant {Table VI):.
Chronic antihypertensive therapy in the mature SHR with a combination of
reserpine and chlorothizide for three .weeks failed to alter t·he activity of the PDE
in the aorta relative to either substrate {Table II). ·Similar results were obtained
for the effect of this treatment on POE activity' in the SHR heart {Table Ill).

Table Iii- Cyclic Nucleotide Phosphodiesterase Activity in the Heart of the SHR and WKY Rats

pmoles hydrolyzed/minims protein± SEM (n)
Animal

Blood Pressure
cGMP PDE

cAMP PDE

1

134.6 ±4.6 (15)

88.8 ± 4.1 (10)

SHR l

190.0 ± 3.3 (23)

65.5 ± 2.2 (25)

4
SHR- T

140.7 ± 3.7 (4)

65.3+4.2 (4)

WKY

110. 1 ±. 9. 8
2

2

\1 0)

72.8±.4.3 (14)
73.0 ±5.3 (4)

3

3

1
Animals used in this experiment were 12 weeks of age.
2

Significantly different from WKY

3

control,~ <0.001.

Significantly different from WKY control, ~

< 0. 010.

4

The treated SHR received 2.5 mg reserpine (base) and 1000 mg chlorothiazide (sodium)/liter in their drinking
water from 6 to 12 weeks of age.

'-"

....

I

Table IV- Cyclic Nucleotide Phosphodiesterase Activity from the Cerebral Cortex of the SHR and WKY Rats

pmoles substrate hydrolyzed/minute/mg protein ± SEM (n)
Animal
cAMP PDE 1

cGMP PDE

WK!-

403.8 ± 43 (4)

599.0±62 (4)

SHR2

403.0 ± 29 (4)

.577. 0 ± 72 (4)

1

1
-6
The substrate concentration was 10 M.
2

The animals used in this experiment were 12 to 15 weeks of age.

<.n

""

~~~~~-

Table V -cAMP Phosphodiesterase Activity in the Aorta of Prehypertensive SHR end Age-mcHched WKY

pmoles substrate hydrolyzed/minute/mg protein

± SEM

(n)

Animal
12 Weeks

6 Weeks

WKY

65.0±6.5 (5)

SHR

46.8±5.2,8)

1
Significant!y different from WKY control,

~-< 0. 05.

2

{

63.5±5.8(7)
1

31. 5 ± 1. 8 (8)

2

Significantly different fram WKY control, P-< 0.001.

V1

w

Table VI - cGMP Phosphodiesterase Activity in the Aorta of Prehypertensive SHR and Age-matched WKY

pmoles substrate hydrolyzed/minute/mg protein :!; SEM (n)
Animal

6 Weeks

12 Weeks

WKY

121.9 ± 17. 1 (6)

116.5 ± 10.9 (7)

SHR

97.6 ± 16.8 (8)

78. 3 ± 7: 9 (8)

1

1
Significantly different from WKY control, P-< 0. 020.

<.n

_;:,..

55

It should be emphasized thai· the independence of PDE activity and the level of
blood pressure shown in J·hese experiments is based on the activity in the tissues
of J·he untreated SHR rather than the WKY. The effed of antihypertensive
treatment on PDE activity in the WKY aorta or heart was not determined.
~denyl Cych;_se Kinetic_:

The experiments discussed in this section describe some of !he basic kinetic
characteristics of adenyl cyclase in the SI-IR and WKY aorta.

Like the PDE

studies, the objectives of these experiments were to resolve conflicts reported
in the literature regarding adenyl cyclase activity in the hypertensive vascular
tissues (64,67) and to further investigate the properties of this enzyme.
pH

Depende_':.~!:ctivity

When the specific activity was determined at the pH

values of 6.8, 7.4, 8.0, and 8.6 the maximum activity for borh the WKY and
SHR enzymes occurred at pH 7.4 (Fig. 9)
Magnesium Dependent Activity

In the presence of saturating concer;trations of ATP

(JmM), the maximum rate of cAMP formation occurred at a magnesium concentration of 8 mM.

It is interesting to note that Mg+2 increases the encyme

activity at concentrations which exceed the concentration necessary to convert
A TP to the ATP-Mg complex. This phenomenon has been observed for adenyl
cyclase from other sources (85,86) and it has been suggested that magnesium is
binding to additional sites which are distinct from the catalytic center.
Substrate Depende11t Activity Adenyl cyclase activity as a function of ATP
concP.ntration yielded simi lor double .reciprocal plots for the SHR and WKY en~ymes
of the, aorta (Fig. 11). The apparent Km's were calculated to be 1.83 and I .80
x 10- 4 M for the WKY and SHR respectively. These values are similar to those

56

Figure 9- The effect of pH on adenyl cyclase activity in the SHR (open circles)
and WKY (closed circles) aorta. The enzymtJ source was a 2200 x g
x 15 min pellet and the substrate concentration was I mM. (n = 2)-

57

0

<!)

:r:

0..

0
0
0

J-lll\ll:::l\1 VoJnVVIXVVIJ lN3:::ll:!3d.

58

+2

Figure 10- The effect of Mg concentration on adenyl cyclase activity from the
SHR {open circles) and WKY (closed circles) aorta. The enzyme
source was a 2200 x g x 15 min pellet and the substrate concentration
was 1 mM. (n = 2) --
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Figure 11 - The effect of substrate concentration on adenyl cyclase activity from
the SHR (open circles) and the WKY (clos:ed circles) aorta. ·fhe enzyme
source was a 2200 x g pe II et. (n = 4)
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reported for a vad®:iy of mammalian tissues which have been estimated to be in
the range of 1 to 5

X

1o-4M (87, 88).

Basal & NaF Stimwilated Activity The basal activity of the enzyme from the SHR
aorta was approxi.mDtely one-half of that observed in the WKY tissue (Table VI}.
The potent betc:-as(mist 1 isoproterenol, failed to activate the enzyme from
either the WKY or SHR in the concentration range of ]Q-7 to 10- 4 M, but both
enzymes were sensitive to activation by lOrnM NaF,, The maximum activities
obtained in the presence of NaF were similar (Table VII}, but the percent increase
in activity far ,the SHR was double that of the WKY.
Intact Cell Stimulation of Adenyl Cyclase

Because of the lack of Fesponsiveness

to isoproterenol in cell free systems, it was necessary to measure to the effects of
various agonists on the formation of cAMP in the intact aorta as described by
Cohen_:.!_~ (72}.

The comparative effects of isoproterenol on the intact SHR and

WKY aortas are shown in Fig. 12.1soproterenol increased the cAMP content
in a dose-dependent manner and had a maximal effect at approximately ]Q-6M.
At the concentrations tested, the cAMP levels of the SHR aorta remained approximately one-half of thai· observed in the WKY.

If the data is replotted as

percent of maximum (Fig. 13}, the dose response curves are virtually identical
with one-half maximal activity occuring at about 3 x JQ-8M for both tissues.
The comparative effects of isoproterenol, epinephrine, and norepinephrine
on cAMP formotion in the SHR and WKY aortas are shown in Table Vlll. At
equal concentrations (Jo-7M}, isoproterenol was the most potent, followed by
epinephrine and norepinephrine.

In all cases, the absolute levels of cAMP

~~~~~--~~~~~~·~

Table VIi- Adenyl Cyclase in Cell-free Preparations of the Aorta from the SHR and WKY Rats

pmoles cAMP formed/minute/mg protein

± SEM

(n)

Assay Condition
WKY

Basal
NaF Stimulated (10 mM)

1

SHR I

3. 98

± 0.55

(4)

47.75

± 5.80

(4)

1.88 ± 0.50 (4)
44.68

± 16.8

2

(3)

1Animals used in this experiment were 9-12 weeks of age.
2

Significantly different from WKY control, P

< 0. 05.

0.

w

64

Figure 12- The effect of isoproterenol concentration on the cAMP levels in the
intact aorta of the SHR (open circles) and the WKY (closed circles).
Each point represents the mean cAMP concentration (pmoles/mg protein)
of 4 separate determinations. Vertical bars indicate the SEM.
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Figure I 3 - The Effect of isoproterenol concentration on f·he cAMP levels in the
intact aorta of the SHR (open circles) and tne WKY (closed circles).
The data from Figure 12 is reploted as percent of maximum response.
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Table VIIi- The Effect of Adrenergic Agents on cAMP Levels in the Intact Aorta of the SHR ond WKY Rats

Agent

cAMP Concentration (pmoles/mg protein) ± SEM (n)

2

%Change

WKY

1.60 ± 0.08 (4)

--

3.50 ± 0.04 (4)

3.26 ± 0. 78 (3)

91.8

6.73

42.4

4.85±0.81(4)

38.8

21.0

3.70 ± 0.

(4)

5.6

SHR

Ba:;a l
Isoproterenol (10

1

-7

M)

Epinephrine (J0- 7M)

2 . 42 .± 0. 16 (3)

3

%Change

± 0.82 (4)

4

92.3

~

Norepinephrine (J0- 1 M)

1.95±0.31 (3)

1
An!mals used in this experiment were 12 weeks of age.
2

The isolated tissues were exposed to the agent for 30 minutes.

3
4

Significantly different from basal levels, P

< 0.001.

Significontly different from basal levels, P

< 0.01.
&;
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was approximately one-half of that observed in the WKY vascular tissue, however,
the magnitude

or !"he

effect calculated on a percent change basis was similar. At

the concentrations used; none of these adrenergic agents affected the steady state
levels of cGMP in the SHR or WKY aorta (fable IX).
Cyclic Nucleotide Levels in the Aorta and the Effect of Antihypertensive Treatment
In the aorf·a q,f the mature (12 weeks of age) SHR the cAMP levels were approximately 50'Yo of that found in the age-matched normotensive control, while
the cGMP levels were significantly elevated (TabJe X).

In the prehypertensive

SHR aorta (6 weeks of age) the cAMP levies were about 30% of that observed in ·
the age-matched controls, but there was no difference in the cGMP concentrations
(Table XI).

It is apparent from this data that the cAMP levels in the SHR aorta

were decreased prior to the increase in blood pressure ancl became even !ower
os the animal grew older and the blood pressure increased further. At the ages
of 6 weeks and 12 weeks the levels in the WKY aorta were similar.

It is also

interesting that the cGMP levels in the WKY had decreased from 6 to 12 weeks,
but the concentration in the SHR aorta remained constant. What this suggests is
that c GMP levels actually increased during the development of hypertension.
In an effort to further evaluate the relationship between the systemic blood
pressure and the ratio of cGMP to cAMP, we examined the effects of three types
of clinically effective antihypertensive agents (Table XII). When compared to
an untreated SHR, both clonidine and hydralazine had a significant antihypertensive effect which was associated with. a statistically significant reduction in the
vascular cGMP concentration, but was without effect on cAMP. Propanolol had
slight pressor effect in the SHR and was accompanied by a decrease in cAMP

....

I

Table IX- The Effect of Adrenergic Agents on cGMP Levels in the Intact Aorta of the SHR and WKY Rats

cGMP Concentration (pmoles/mg protein ) .± SEM (n)

2
Agent
SHR

0.289 ± 0.05 (4)

0. 382

± 0. 10 (3)

0.275 ± 0. 07 (4)

7
Epinephrine (10- M)

0.471

± 0.09

0.286 ± 0.01 (4)

7
Norepinephrine (10- M)

0.404 ± 0.04 (4)

-7

isoproterenol (10

M)

3

WKY

0.399.±0.61 (4)

Basal

I

(4)

0.299

± 0. 01 (4)

1
Animals used in this experiment were 12 weeks of age.
2

The isolated tissues were exposed to the agent for 30

3

minute~.

Statistical compadsions were made with respect to the basal ievels.

Cl

'
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Table X- Cyclic Nucleotide Levels in the Aorta of the SHR and WKY Rots

1

Cyclic Nucleotide Concentration (pmoles/mg protein) ±SEM (n)
Animal

Blood Pressure
(mm Hg)
cAMP

WKY

134.6+4.6

3.59 .±0.57 (5)

SHR

190.0+3.3

1.60 ± 0.21 (5)

cGMP

2

0.233 ± 0.06 (7)
.
3
0.396 ±0.04 (4)

1The animals used in this experiment were 12 weeks of age.
2
3

Significantly different from the WKY

control,~ <0.01.

Significantly different from the WKY control, P < 0. 05.

.....

Table XI - Cyclic Nucleotide Levels in the Aorta of the Prehypertensive SHR and WKY Rats

1

Cyclic Nucleotide Concentration (pmoles/mg protein}± SEM (n}
Animal

Blood Pressure
(mm Hg}
cAMP

cGMP

WKY

121.4 + 6.4 (6}

3,97

± 0.32

SHR

128.9 + 2.9 (7}

2.71

± 0.18 (5} 2

(6}

0.439 ±.0.05 (5}
0. 397 ±. 0. 10 (7}

1
The animals used in this experiment were 6 weeks of age.
2

Significantly different from the WKY control i

~-< 0. 01.

;:j

Table XII- Cyclic Nucleotide Levels in the Aorta of the SHR --the Effect of Antihypertensive Treatment

Cyclic Nucleotide Concentration (pmoles/mg protein)± SEM (n)
Treatment

Blood Pressure
(mm Hg)
cAMP

I

cGMP

190.0+3.3

1.60%. 0.21 (5)

0. 396 .,_ 0. 04 (4)

Cl on1;d.me 1.

146.4 + 5.6

I. 14%.0.06 (5)

0.234%.0.04 (5)

Hydralazine 1

139.4 + I. 0

1.42 ± 0. 13 (5)

0.221 ± 0.03 (5)

213.0+9.9

0.89 ± 0.20 (5)

Control

Propanolol

1

3

2
2

0. 308 ± 0. 03 (5)

1The SHR received either clonidine HCI (5 mg/liter), hydralazine HCI (100 mg/liter), or propanolol HCI (600 mg/
liter) in their drinking water from 9 to 12 weeks of age. The control SHR received water only.
2

3

Significa~tly different

from the control SHR, P-< 0. OJ.

Significantly different from the control SHR,

~-< 0. 05.

'I
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with no change in the concentration of cGMP.

Using different antihypertensive

agents, Amer (89) has made similar observations in the Goldblatt hypertensive model.
A rather confusing aspect of this experiment relates to the response of the SHR to
chronic oral propanolol administration, for this agent is an effective drug in the
treatment of essential hypertension in man. This phenomenon has been observed
by other investigators (90,91), however, neither the antihypertensive mechanism
in man or the lack of effectiveness in the SHR have been adequately explained.
Cyclic Nucleotide Levels in the Heart
The major emphasis of this study has been concerned with cyclic nucleotide
metabolism in the vascular tissues of the SHR, but for comparative reasons we
have examined the steady state levels in the cardiac tissue to confirm the reports
of Amer (64) and Ramanathan and Shibata (67) (Table XIII). As in the aorta, cAMP
levels in the heart of the mature SHR were significantly lower than that in the WKY,
but in contrast to the aorta, there was no difference in the cGMP concentration.
Vascular Protein Concentration
The data described in the previous sections were calculated in terms of the
protein concentration and it is possible that the change in experimental conditions
could have affected tissue protein content. To test this possibility, we performed
experiments to determine whether the protein concentration (mg protein/mg wet
tissue) differed under the various conditions of the study (Table XIV). The protein
concentration in the aorta doub!ed from 6 to 12 weeks of age, but there was not a
significant difference between the WKY and SHR tissues,

Likewise, the differences

in the, heart were not significant (Table XIV).
With respect to the antihyperl·ensive treatment experiments, treatment did not

75

alter the protein concentration with any of the agents when compared to .the
SHR receiving no drug therapy. (Table >N).

1
Table XIII- Cyclic Nucleotide Levels in the Heart of the SHR and WKY Rats

Cyclic Nucleotide Concentration (pmoles/mg protein) ± SEM (n)
Animal
cGMP

cAMP

WKY

3.43 ± 0.30 (5)

SHR

2.21 ± 0. 16 (8)

2

0. 676 ±

o. 06 (5)

0.538 ± 0. 07 (5)

2

1The animals used in this experiment were 12 weeks of age.

2

Significantly different from the WKY control,

~

<

0. 05.

'-./

o-

Table XIV - Protein Concentration in the Heart and Aorta of the SHR and WKY Rats

Protein Concentration (mg/mg tissue )
Animal

SHR

Aorta

6

0. 156 ± 0. 006 (4)

0. 036 ± 0. 008 (3)

12

o. 134 ± 0. 007 (4)

0. 063 ± 0. 020 (3)

o. 158 ± 0.018

(5)

0. 032 ± 0. 022 (3)

0 • 131 :r_. 0 • 0"
, ~0 ,.,.,
\.:>1

0. 063 ± 0. 005 (3)

6

12
l

+ SEM (n)

Age
(weeks)
Heart

WKY

l

mg wet weight of tissue.

:::J

Table

)01 -

Protein Concentration in the SHR Aorta -- the Effect of Antihyperl·ensive Treatment

1
.li

Protein Concentration (mg/mg tissue)

SHR Control

0. 062 + 0. 005 (5)

Clonidine

0.066 ± 0.018 {5)

± SEM

(n)

Hydralazine

Profiano lo I

0. 064 ± 0. 007 (5)

0. 067 ± 0. 003 {5)

1
See Table XII for a complete description of the antihypertensive treatment.

"-!
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DISCUSSION

Th"' data presented in this study have confirmed the previous reports of Amer (64,65)
and Ramanathan and Shibata (67), namely, that there are significant alterations in
the metabolism of cAMP and cGMP in the aorta of the SHR which could be related
to the development of hypertension. The current hypotheses describing this relationship envisions vascular contraction to be the result of an increase in the tissue leveh,
of cGMP or a decrease in cAMP, whereas, an increase in cAMP or a decrease in
cGMP leads to relaxation of vascular smooth muscle (64,65). Therefore, the increase in cGMP and decrease in cAMP that we have observed in t·he carla of the
SHR might be related to the increased vascular tone and peripheral resistance in
these animals.
However, as discussed earlier, the enzymatic mechanism(s) by which the cyclic
nucleotide metabolism was altered was unclear. Thus, one of the specific. aims
of this research was not only to clarify, but to give additional insight concerning
the relative roles of adenyl cyclase and cyclic nucleotide phosphodiesterase in
modifying the intracellular concentration of cAMP in the aorta of the SHR. The
second objective was to determine whether there was any correlation between the
level of systemic blood pressure in the SHR and the cGMP and cAMP levels in the
aort<J.

Prior to discussing these objectives, we would like to elaborate further on

the possible role of these cyclic nucleotides in the regulaticon of vascular smooth
muse Ie tone.
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The Role of Cyclic Nucleorides in the Regulation of Vascular Smooth Muscle Tone
Sutherland and his colleagues (92) have described three criteria which should be
satisfied if cAMP and cGMP are acting as mediators of a particular hormonal response:
(a) the hormone should stimulate either adenyl cyc•lase or guanylate cyclase in
broken-cell preparations; (b) the hormone should alter the tissue levels of the
respective cyclic nucleotide in an appropriate physiological dose and this effect
should be temporally correlated with the physiological response; and (c) the cyclic
nucleotide should reproduce the effect of the hormone when added to an intact-cell

I

preparation of the particular tissue. The validity of this criterion should be guestioned,
though, since the cyclic nucleotides do not pass through the cell membranes to an
appreciable extent. Therefore, it would be difficult to determine whether the effect
was an extracellu lor or in trace II u lor one.
The ability of hormones to activate adenyl cyclase in cell-free preparations is a
highly labile property of the enzyme and the initial attempts to stimulate the enzyme
from vascular smooth muscle honogenates were unsuccessful (93,56). More recently,
however, Amer (64) and Ramanathan and Shibata (67) have demonstrated activation
with relatively high concentrations (Jo-6 to JQ-5M) of isoproterenol, epinephrine,
and glucagon. We were unable to reproduce this response for adenyl cyclase from
either the SHR or WKY aorta, in spite of the fact that the method of enzyme preparation and assay conditions were similar. Using the same technigues, Cohen and
Berkowitz (72) were also unable to demonstrate hormonal sensitivity.

It is not clear

why we could not demonstrate activation, and the use of other homogenization
technigues (Polytron or glass pestle) yielded similarily inactive preparations. This
loss of sensitivity to hormonal stimulation is generally considered to result from the

81

dissociation of the receptor from the catalytic unit of the enzyme during homogenization of the tissue. This phenomenorn has been observed in other tissues (88) and
because of the extreme lability to hormonal stimulation in cell-free systems, the
failure to observe activation is not necessarily considered as negative evidence.
There have not been any reports in the literature of a hormone-·sensitive guanylate
cyclase in cell-free preparations from any tissue, although there are numerous
incidences of hormone-induced changes in cGMP levels in the intact cell.
With regard to the second criterion, evidence has been presented earlier (see
lntroducf·ion) which stresses the relationship between the ability of vasoactive
hormones to relax vascular smooth muscle via an increase in cAMP or increase
vascular tone through an increase in cGMP or a decrease in cAMP. Significant exceptions, however, have been reported in the literature. For example, Seidel end
Addison (94) were unable to detect changes in the tissue levels of cAMP associated
with the phenyl~phrine-induced contraction of the pig coronary artery, but an
epinephrine-induced contraction was accompanied by a rise in cAMP. Daniel and
Crankshaw (95) found that cAMP levels remained constant in spite of contraction of
the rabbit aorta by serotonin and the subsequent relaxation by isoproterenol. Using
isolated canine femoral arteries, Diamond (96) reported that phenylephrine-induced
contractions had no effect on the tissue levels of cAMP, while, relaxation by papaverine and nitroglycerin actually lowered cGMP with no alteration of cAMP.
On the other hand, our experiments with the isolated rat aorta demonstrated
that epinephrine and isoproterenol in.creased the levels of cAMP, wherease, norepinephrine was without effect. This suggests that the vaso-relaxant effects of these
beta- adrenergic agents could indeed be related to the ability of these agents to
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increase the intracellullar levels of cAMP. Since norepinephrine was inactive in
both the SHR and WI<Y tissues, this suggests that the vasoconstrictive action of this
agent is independent of the cAMP system.

If there was a relationship between cAMP

levels and vascular contraction, the levels should have decreased in the presence
of norepinephrine.
As discussed by Vesin and Harbon (97) and Andersson (98), many of these inconsistencies reported in the literature could result from the preoccupation with the
total tissue levels of the cyclic nucleotide as a criterion ior establishing a cause and
effect relationship.

It is unlikely,however, that the nucleotides are uniformily

distributed within the cell, and it is possible that a substantial portion is sequestered
in a metabolically inactive compartment. A change in the concentration in a
metabolically active pool could pres1J111ed to be the principal determinant affecting
the contractile elements of the cell, whereas, chi:mges in the total concentration
could be unrelated to the degree of contractile tone.
De>pite the limitations of the third criterion, exposure os isolated vessels to cAMP
has generally reproduced the effects of hormones which induce vascular relaxation.
Triner

?! ~· (56) demonstrated that cAMP relaxed norepinephrine-contracted aortas.

Similar results were described by Kreye and Schultz (99) for the same preparation,
and Cohen .and Berkowitz demonstrated that cAMP antagonized the serotonin-induced
contraction (44).

Levy found that dibutyryl cAMP relaxed a PGE2 contracted rabbit

aorta, but prevention of contraction required a prolonged preincubation with the
cyclic nucleotide (6 I).
The exposure of isolated vessels to cGMP has not supported the hypothesis that
this nucleotide is involved in the contraction of vascular smooth muscle.

Cohen and
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Berkowitz (44) were unable to observe contraction of the rat aorta with cGMP
or the dibutyryl derivative; however, the cyclic nucleotide relaxed the serotonincontracted preparation.

It is possible, though, that this response has resulted

from an effect of cGMP at the level.of the cell membrane rather than a true
intracellular acHon because of permeability problems. A similar argument could
also advanced with respect to the effects of cAMP. An additional problem has
arisen out of the observation that adenosine alone relaxes vascular smooth muscle
(99). This implies that the relaxant effects of the cyclic nucleotide could result
from a nonspecific action of the nuc Ieos ide component.
It is very intere$ling to note that these investigators have extended this type
of experiment to the isolated aorta of the SHR and have found that the hyperh~nsive
· - l'

vessel was resistant to the relaxant effects of both cAMP and cGMP. Their interpref·ation was that the defect altering the vascular reactivity in the hypertensive
vessel is distal to the effects of the cyclic nucleotide. This argument is contrary
to the evidence in the literature.(64,65,67) and also our data which show low
levels of cAMP in the SHR vessel.
Admittedly, the evidence supporting these criteria is incomplete, but many
of the controversies appearing in the literature probably result from an oversimplification of the mechanisms regulating vascular contractility. The evidence
that we hove reported here, albeit circumstantial in nature, is supportive of the
hypothesis that cAMP and cGMP could function in the control of vascular reactivity.
The Relationship Between Vascular Cyclic Nucleotide Levels and the Blocd Pressure
It may be argued that the increased ratio of cGMP to cAMP seen in the aorta
of the SHR results from the hypertensive condition rather than being a causative

\

\
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factor. We have attempted to resolve this problem by determining the levels in
the aori·a of prehypertensive and fully hypertensive SHR. As additional evidence,
the cyclic nucleotldes levels were measured subsequent to chronic antihypertensive
therapy. As originally reported by Ramanathan and Shibata (67}, we found the
cAMP levels in the prehypertensive SHR to be lower than that observed in the
age-matched WKY control. As the animals matured and the b!ood pressure rose
in the SHR, the cAMP concentration decreased further, while the levels in agematched controls did not change. This suggests that cAMP is playing a role in
the development of an increased vascu far resistance and subsequently hypertension.
On the other hand, cGMP levels were initially normal in the prehypertensive aorta.
However, as the SHR matured, cGMP levels remained constant, but the levels
in the WKY aorta decreased to a new low level. This implies that cGMP levels
in the SHR remained elevated as a result of the increase in blood pressure. Additional evidence favoring this interpretation is derived from the antihypertensive
experiments. Chronic therapy with two types of agents (clonidine and hydralazine}
decreased the cGMP levels in the SHR aorta, but had no effect on the vascular cAMP
concentration, when compared to the untreated SHR control. It may be debated
as to whether this effect on cGMP occurred as a result of the change in blood
pressure per ~or from o direct effect of the drugs. An analysis of the effects
of these drugs on the normotensive vessel should clarify this point, but th<l fact
that these agents, which have differing m<lchanisms of action, had the same
effect further supports the idea that c.GMP levels are changing secondarily to
the degree of blood pressure. It is also interesting that chronic propanol of treatment neither lowered the blood pressure or had any effect on the vascular concen-
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tration of cGMP.

In fact, the slight pressor effect of propanolol was ac-

companied by a further decrease in the concentration of cAMP.
Jhe Role of Cyclic Nucleotide Phosphodies~
The steady stole tissue levels of cyclic nucleotides will be determined by the
algebraic sum of the rate of synthesis by the cycloses and the rate of hydrolysis
to the 5' metabolite by POE. Our data have shown, unequivocally, that the
specific activity of the high affinity form of cAMP POE in the SHR aorta was depressed; being approximately one-half of that measure in the normotensive WKY
aorta. This result is similar to that reported by Ramanathan and Shibata (67), but
contrary to the work of Amer (69,70), who found the activity to be greater than in
the WKY aorta.

Unforlunately, Amer reported the activity of the high affinity form

of POE as percent of the total activity rather than as the absolute specific activify
which makes it difficult to compare with our data.
Furthermore, we were not able to detect any difference in the properties of
the enzyme from the two sources in terms of the apparent km value, pH optima,
and magnesium ion deoendency. The only difference was found in the V max value
which was significantly lower in the SHR aorta as compared to the WKY control.
Since the protein contents of the aortas were not significantly different, this
implies that there was a decrease in the amount of POE protein in the hypertensive smooth muscle cell and a decrease in specific activity.

It is also possible

that there is a decrease in the activity of a calcium-dependent modulator protein
which has been described to regLolate .POE activity in a variety of tissues (81),
but this was not examined in these experiments.
Thus, the capaCity of POE to hydrolyze cAMP is decreased in the SHR aorta.
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The consequence. of this effect is highly dependent upon the rate at which cAMP
is formed by adenyl cyclase,

It is generally accepted that this step is rate-

limiting and since the amount of adeny cyclase present in the SHR aorta was also
found to be one·-half of that in the WKY aorta, this would suggest that PDE is not
a determining foetor in the steady-state levels of cAMP,
Pretreatment of the SHR with reserpine and chloroth iazide prevented the rise
in systemic blood pressure and there was a trend towards an increase in cAMP PDE
activity, but the results were not significant. It is possible, though, that these
agents might have had a direct effect on PDE activity irrespective of the level of
blood pressure. This latter effect might have been observed if the WKY controls
were treated with these agents.

rurthermore, the specific activity of cAMP PDE

in the prehyperter.sive SHR aorta was significantly lower tl--an that in the agematched control. This data supports the observation that cAMP levels were independenl·
of the systemic blood pressure.
The activity of cGMP PDE generally paralleled that of the cAMP dependent
activity.

it is not known if this represents an actual decrease in the amount of

cGI'v\P PDE protein which is distinct from the cAMP PDE enzyme protein, or
whether the substrates are being acted upon by a nonspecific PDE. Recently,
Hardman.=!'_~

(100) have describ"'d the separation of relatively specific forms of

cGMP PDE and cAMP PDE from the pig coronary artery by DEAE-cellulose
chromatography. This suggests that the former interpretation is.correct, but
further studies on purified enzyme preparations ore necessary to clarify this point.
The Role of Adenyl Cyclase
As discussed above, adenyl cyclase activity is the rate limiting factor in
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regulating the intracellular levels of cAMP. Thus, those factors which regulate
the activity of the enzyme would a priori be important in the regulation of
vascular smooth muscle tone. These factors could include: (a) the amount of
enzyme present; (b} regulation by the intracellular concentration of ATP and
cofactors; (c) changes in affinity for the substrate or cofactors; (d) the number
of hormonal binding sites (receptor unHs); (e) the affinity of hormones to these
binding sites; and (f) the abilil"y of ;he receptor unit to couple with the catalytic
site to initiate enzyme activity.
Our conclusions about what the role of adenyl cyclase plays in the increased
vascular tone observed in the SHR is based primarily on the fact that there is decreased basal activity of adenyl cyclase in the SHR aorta. This lowered activity
is not due to a change in the kinetic behavior of the enzyme (see below) but by a
decrease in the amount of enzyme present in the SHR aorta. Secondly, this
decreased amount of enzyme correlated with the decreased levels of cAMP and
cAMP PDE activity found in the SHR aorta.

Perkins, though, has argued that

there is not a clear correlation between the basal activity and the concentration
of cAMP in a variety of tissues (88), and Schramm and Maim (101) have suggested
that it represents an artifact due to pertubation of the enzyme during homogenization,
rather than a true hormonal independent activity. In support of the latter view are
the observations that cAMP levels remain constant in cell culture (102) or in isolated
cell preparations in the absence of hormonal influences. Since our experiments
compared the relative activities in the same tissue and under identical conditions,
it is certain that we are measuring essential differences in the basal activity of adenyl
cyclase as opposed· to random artifactual variations in enzyme activity.
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It has been assumed by some investigators that activation of the catalytic site
by NaF causes full expression of the enzyme activity, and would, therefore, be
representative of the total amount of enzyme present. The evidence for this
assumption is based on the observation that the activity in the presence of NaF
is generally greater than that obtained by hormonal stimulation.

However, Birnbaumer

.:.!". ':'.!_, (85) and Hynie and Sharp (103) demonstrated that the enzyme from the frog
bladder epithelium was more sensitive to vasopressin than NaF. Similarily, Perkins
and Moore, (!04) have shown that Triton X-100 was more effective than NaF as an
activator of adenyl cyclase from the rat cerebral cortex. Therefore, our results which
have shown similar WKY and SHR activities in the presence ofF- should not necessarily be ini·erpreted that the total amount of enzyme protein is comparable in the
. aortas from both animals.

In contrast, the basal activity da.ta suggest·s that the con-

centration of adenyl cyclase in the SHR aorta is lower than that in t·he normotensive
control tis$ue.
Although we did not determine the concentrations of ATP or magnesium in
cells of the aorta, it is unlikely that their concentrations in the cytosol would
change to the degree that is necessary to alter the activity of adenyl cyclase.
The concentration of ATP in the cell has: been estimated to be approximately
5 mM, whereas, the concentration of intracellular magnesium is about 40 mM.
These concentrations are in far excess of that necessary for optimum activity of
adenyl cyclase.
In addition, the Michaelis constants of adenyl cyclase for the substrate were
in close agreement for both the SHR and WKY enzymes as were the pH and magnesium dependent activities. Therefore, changes in the apparent affinity for the
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subslrate or cofactors can not be implicated as possible mechanisms responsible for
altering the acti'1Hy of adenyl cyclase in the SHR aorta.
Our studies on the intact aorta indicate a significant difference in the ability
of ~to-adrenergic agonist ta increase cAMP levels in the SHR vessel compared
to the WKY.

Th'~

maximum effect of ispproterenol in the SHR aorta was approximately

one-half of that observed in the WKY, but the dose response curves for therespective tissues were not shifted. These results could be interpreted in several
ways. One possible explanation is that the apparent affinity of the hormone for
the receptor unit is altered in the SHR vascular smooth muscle cell. However,
we failed to observe a shift in the SHR dose response curve for isoproterenol to the
right of the WKY curve. The results could also be explained by a loss
in the number of receptors available for agonist binding and studies to determine
the number of binding sites would be revealing in this respect.

It is also possible

that there is a defect in the ability of the hormone-bound receptor unit to couple
with the catalytic unit. We did not, however, design experiments to test this
possibility.

Considering the basal activity data discussed above, it is more likely

that the decreased sensitivity of the SHR vascular adenyl cyclase to isoproterenol
results from the decrease in the concentration of enzyme protein in the SHR aorta.
To emphasize this latter point, it is of considerable interest that the basal
adenyl cyclase activity, the basal levels of cAMP, the beta-adrenergic sl'imulated
levels of cAMP, and the specific activity of cAMP PDE in the SHR aorta were all
observed to be approximately one-half of that in the normotensive aorta. This
observation further supports our origina I hypotheses described above that the
decrease in the ability of the SHR aorta to relax results from a decrease in the

90

concentration of adenyl cyclase protein at the level of the vascular smooth muscle
cell membrane.

II
j

CONCLUSIONS

cAMP and cGMP have been proposed to be second messengers responsible,
!

ot least in part, for the actions of hormones which modify vascular smooth muscle

1

tone. Specifically, it has been suggested that an increase in the ratio of cGMP
to cAMP leads to contraction of vascular smooth muscle, whereas, the converse
would favor relaxation and vasodilation. In this regard, there have been recent
reports of an elevated ration of cGMP to cAMP in the vascular tissues of the stress,
DOCA, neurogenic, and spontaneously hypertensive rats which could explain
the increased vascular smooth muscle tone and peripheral resistance in these
animals. The present study has confirmed this observation in the aorta of the
spontaneously hypertensive rot {SHR) and has attempted to characterize the
enzymes involved in the metabolism of cAMP. In addition, we have examined
the relationship between the level of systemic blood pressure and the ratio of
these cyclic nucleotides in the SHR aorta.
Using a combination of cell-free and intact cell assay systems, we have
demonstrated that the activity of adeny cyclase, both basal and beta-adrenergic
stimulated, was significantly decreased in the SHR aorta. The apparent affinity
of isoproterenol for the receptor, the km for ATP, and the magnesium and pH
dependent activities were similar to that observed in the control aorta. There was
a decrease in the activity of the low km form of PDE in the SHR aorta; however,
there was no difference in the apparent affinity for cAMP of in the magnesium or
pH dependent activities. On the basis of this data, we have proposed that the
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low cAMP levels in the SHR aorta, result from a decrease in the concentration
of adenyl cy~lase protein in the vascular smooth muscle. The concentration of
POE protein has apparently decreased secondarily to be consistent with 1·he new
rate of cAMP formation.
Compared to the normotensive control, cAMP levels in the SHR aorta were
initially low in the prehypertensive SHR and decreased further as the blood
pressure increased. The levels in the control remained constant throughout
the sameperiod. At the prehypertensive age, cGMP concentration in the SHR
was similar to that observed in the control, but as the blood pressure increased
in the SHR, cGMP remained at this level while the concentration in the agematched controls diminished. Chronic antihypertensive therapy in the mature
SHR did not affect cAMP levels, but lowered cGMP level; to that found in the
normotensive vessels. Based on these studies, it was suggested thctt the alteration
in cAMP metabolism has occurred prior to the increase in" blood pressure while
cGMP levels are changed as a result of the hypertension.

BIBLIOGRAPHY

1.

Kannel, W.B., Gordon, T. and Schwartz, M.J., Am. J. Cardiology 27: 335,

1971.
2.

Kannel, W.B., Castelli, W.P. and McNamera, P.M., N. Engl. Med. 287:

781, 1972.
3.

Lew, E.A., in Hypertension Manual (J.H. Laragh, ed.), pp. 43-70, Yorke
Medical Books, New York, 1973.

4.

Veterans Administration Cooperative Study Group on Antihypertensive Agents,
J. Am. Med. Assoc. 213:1 143, 1970.

5.

Schweitzer, M, D., Clark, E. G., Gearing, F. R. and Perera, G.A., ~·
Chron. Dis. 45:1093, 1962.

---6.

P:att, R., ~ancet .2_:899, 1963.

7.

Vital Statistics of the United States, Section 6 Mortality Statistics, U.S.
1)-;,partrnent of Health, Education, and Welfare,Publ'ic-HeCilth Servic,
Bethesda, MD., 1967.

8.

Prior, A.M., Evans, J.G., Harvey, H.P.B., Davidson, F. and Lindsey, M.,
~~~gl. J. Med. 279:515, 1968.

9.

Guyton, A.C., Cowley, A.W., Coleman, T.G., DeClue, J.W., Norman,
R.A. and Manning, R. D., Chest 65:328, 1974.

0m 1.

10.

Laragh, J, H.,

11.

Dunn, M.J. and Tanner, R. L., Kid. Int.

12.

Med. 55:261, 1973.
~:317,

1974.

Genest, J., Boucher, R., Kuchel, 0. and Nowaczynaki, S,, Can. Med.
~)C,

J, 109:475, 1973.

13.

Kaplan, N.M., J. Am. Med .. A~. 231:167, 1975.

14.

Padfield, P.L., Brown, J.J., Lever, A. F., et al., Lancet .!_:548, 1975.

15.

Widimsky, J., Felfarova, M.H. and Fejfer, Z., Cardiologic (Basal) ~:381, 19.57.

94

~:299,

16.

Eich, R. H. and Cuddy, R.P., Circulation

17.

Pfeffer, M. A, and Frohlich, E. D., Cir. Res. 32;· Suppl. 1:29, 1973.

18.

Coleman, T.G., Bower, J.D., Langford, H.G. and Guyton, A.C.,
Circulation 42:509, 1970.

19.

Folkow, B., Clin. Sci.

20.

Goldblatt, H., J. Exp. Med. 65:671, 1937.

21.

De Ouattro, V., Campese, V. and Antonaccio, M.J., in Cardiovascular
Pharmacology (M.J. Antanaccio, ed.), pp. 185-215, Raven Press, New York,
1977.----

22.

Grollman, A., Harrison, T.R. and Williams, J.R., J. Pharmacal. Exp. Ther.
69:149, 1940.

23.

Beilin, L.J. and Ziakas, G., Clin. Sci. 42:579, 1972.

24.

Smirk, F. H. and Hall, W. H., Nature (Land) 182:727, 1958.

25.

Okamoto, K. and Aoki, K., Jap. Cir. J. 27:282, 1963,

26.

Nakamura, K., Gerold, M. and Thoenen, H., Arch. Pharmak. 27.1:157, 1971.

27.

Spector, S., Tarver, J. and Berkowitz, B., in Spontaneous Hypertension,
(K. Okamoto, ed, ), pp. 41-45, lgaku Shain Ltd., Tokyo, 1972.

28.

Shiono, K. and Sokabe, H., Am. J. Physiol. 231:1295, 1976.

29.

Undenfriend, S. and Spector, S., Science

30.

Wolf, R.L. Mendlowitz, M. and Robez, J., Circulation 36:272, 1967.

31.

Bristow, J.D., Honour, A.J., Pickering, G., Sleight, P. and Smyth, H.S.,
Circula!ion 39:48, 1969.

32.

Folkow, B., Hallbock, M..;, Lundgren, Y. and Weiss, L., Acta Physiol. Scond.
81:373, 1970.

~:1,

1966.

1971.

176:1155, 1972.

~

33.

Bohr, D.F., Fed. Proc. 33:127, 1974.

34.

Okamoto, K., et al. , Jap. Cir. J. 30:987, 1966.

35.

Doyle, A.E., Am. Heart. J.

45:363, 1.953.

95

36.

Daley, J,J. and Duff, R.S., Clin. Sci.

19:457, 1960.

37.

Laverty, R., Proc. Univ. Otago Med. School 39:23, 1961.

38.

McGregor, D. D and Smirk, F. H., in Medicinal Chemistry, Vol 7, (G.
DeStevens, ed.), pp. 2-78, Academic Press, New York, 1967.

39.

Lais, L.J"' Bhatnagar, R. and Brody, M.J" Cir. Res. 34, Suppl. 1:155, 1974.

40.

Clineschmidt, B.V" Geller, R.G" Govier, W.C. and Sjoerdsma, A.,
Eur. J . Pharmacal. 10:45, 1970.

41.

Spector, S., Fleisch, J.H. and Mailing, H.M., Science 166:1300, 1969.

42.

Shibata, S., Kurahaohi, K. and Kuchii, M., J. Pharmacal. Exp. The!:_:

185:406, 1973.
43.

Levy, .J.V., ~ur. J. Pharmacal. 3~:117, 1974.

44.

Cohen, M.L. and Berkowitz, B.A., J. Pharmacal. Exp. Ther.

45.

Rail, T.W., Sutherland, E.W. and Berthet, J., J. Bioi. Chem.

46.

Robizon, G.A., Bul·cher, R.W. and Sutherland, E.W., in
Academic Press, New York, 1971.

47.

Iverson, L.L., J. Neurochem. 29:5, 1977.

48.

Georgi.!, W.J., Polson, J.B., O'Toole, A.G. and Goldberg, N.D., Proc.
!'-Ia t. Acad. Sci. 66: 398, 1970.

49.

Go!dberg, N.D., 0' Dea, R. R. and Haddox, M. K., in Advances in Cyclic
Nucleotide Research (P. Greengard and G.A. Robison, eds.), Vol 3, pg.
155, Raven Press, New York, 1973.

50.

Robison, G.A., Butcher, R.W. and Sutherland, E.W., Ann. N.Y. Acad.
Sci. 139:703, 1967.

191:147, 1974.

~yclic

224:463, 1957.
AMP,

---51.

Robison, G.A., Butcher, R.W., Oye, 1., Morgan, H.E. and Sutherland,
E.W., Mol. Pharmacal. 1:168, 1965.

52.

Mayer, S.E., Namm, D. H. and Rice, L., Cir. Res. 26:225, 1970.

53.

Skelton, C.L., Levey, G.S. and Epstein, D.E., Cir. Res. 26:35, 1970.

54.

Ahren, K., Hjalmarson,· A. and lsaksso11, 0., Acta Physiological Scand.
82;79, 1971;

96

55.

George, W,J., Wilkerson, R.D. and Kadowitz, P.J., J. Pharmacal. Exp.
Th::_. 184_7.28, 1973.

56.

Triner, L., Vulliemoz, Y., Verosky, M., Habif, D.V. and Nahas, G.G.,
li~~· _::::817, 1972.

57.

Andersson, R., Acta pharmac. tox.32:321, 1973 .

.58.

Sprague, D. H., Yang, J.C. and Ngai, S. H., Anesthesiology 40:162, 1974.

59.

Sprague, D. H. and Ngai, S. H., Anesthesiology 40:336, 1974.

60.

Triner, L., Nahas, G.G., Vulliemoz, Y., Overweg, N., Verosky, M.,
Habif, D.V. and Ngai, S.H., Ann. N.Y. Acad. Sci. 185:458, 1971.

61.

Levy, J.V., Res. comriwn .. chem. pathol. Pharmacal. !3.:297, 1973.

62.

Sutherland, C.A., Schultz, G., Hardman, J. G. and Sutherland, E. W .,
fed. Proc. 32:773, 1973.

63.

Dunham, E. W., Haddox, M. K. and Goldberg, N.D., Pro c. Nat. Acad. Sci.
?.!_:815, 1974.

64.

Amer, M.S., Science

65.

Arner, M.S., Gomoll, A.W., Perhach, J.L., Jr., Ferguson, H.C. and
tv\cKinney, G.R., Proc. Nat. Acad. Sci.?.!_:4930, 1.974.

66.

Arner,- M.S., Doba, N. and Reis, D.J., ibid. 72:2135, 1975.

67..

Ramanathan, S. and Shibata, S., Blood Vessels _!..!_:312, 1974.

68.

Wollenberger, A., Ristow, 0. and Schoffa, G., Arch. Gesamte Physiol.
iv\enschen Tiere ~:399, 1960.

69.

Lowry, O.H., Rosebrough, H.J,, Farr, A.L. and Randall, R.J., J. Bioi.
Chem. 193:265, 1960.

179:807, 1973.

·-·---

Biochemistry..!_~:

70.

Thompson, W.J. and Appleman, M.M,,

133, 1971.

71.

Murad, F., Manganiello, V. and Vaughn, M., Proc. Nat. Acad. Sci.
68:736, 1971.

72.

Cohen, M. L., Blume, A. S, and Berkowitz, B.A., Blood Vessels

73.

Cyclic AMP Assay Kit, Amersham/Searle Corp. ·

~:25,

1977.

97

74.

Gilman, A.G., Proc. Nat. Acad. Sci. 67:305, 1970.

75.

Freis, E. D. and Ragan, D., Proc. Soc. Exp. Bioi. Med.

76.

Appleman, M.M. and Teraski, W.L., in Advances in Cyclic Nucleotide
Research, (G~I. Drummond and P. Greengard eds.), pp. 153-162, Raven
Press, New York, I 975.

77.

D'Auriac, A. G. and Meyer, P., Life Sci. 12:233, 1973.

78.

Cheung, W.Y., J. Bioi. Chern. 246:2859, 1971.

79.

Cheung, W. Y., Biochemistry

80.

Hidaka, H., Asana, T. and Shimamoto, T., Biochim. Biophys. Acta. 377:

,Z: 1079,

150:422, 1975.

1967.

103, 1975.
81.

Robison, G.A., Butcher, R.W. and Sutherland, E.W., in Cyclic AMP, pg.
87, Academic Press, New York, 1971.

82.

Wells, J.N., Baird, C.E., Wu., Y.J. and Hardman, J.G., Biochim.
Biophys. Acta 384:430, 1975.

83.

Thompson, W.J. and Appleman, M.J., Biochemistry .!_£:311, 1971.

84.

Thompson, W.J. and Appleman, M.J., J. Bioi. Chern. 246:3145, 1971.

85.

Birnbaumer, L., Pohl, S.S. and Rodbell, M., ibid. 246:1857, 1971.

86.

Drummond, G.l. and Duncan, L., ibid. 245:976, 1970.

87.

Birnbaumer, L., and Pohl, S.S. and Rodbell, M., ibid. 244:3468, 1969.

88.

Perkins, J.P., in Advances in Cyclic Nucleotide Research, Vol. 3 (P. Greengard and G.A. Robison, eds.), pp. 1-56, Raven Press, New York, 1973.

89.

Amer, M.S., Perhach, J.L., Gomoll, A.W. and McKinney, G.R.,
Pharmacologist ~:288, 1974.

90.

Levy, J.V., Am. J. Med. ~:779, 1976.

91.

Tabei, R., Spector, S., eta!., ~lin. Pharmacal. Ther . .!.!_:269, 1970.

92.

Suthedand, E. W., Robison, G. A. and Butcher 1 R. W., Circulation 37:279

----

1968.
93.

Schonhofer, P.S., Skidmore, I.F., Fern, J. and Fleisch, J.H., J. Pharm.
Pharmacal. 23:28, I 971.

98

94.

Seidel, C.l. and Addison, T., Fed. Proc. 33:451, 1974.

95.

Daniel, E.E. and Crankshaw, J., Blood Vessels _!2:295, 1974.

96.

Diamond, J., in The Biochemistry of Smooth Muscle, (N. L. Stephens, ed.),
pp. 346-360, University Park Press, Baltimore, MD, 1977.

97.

Vesin, M.F. and Harbon, S., Mol. Pharmacol. 10:457, 1974.

98.

Andersson, R. and Nilsson, K. B., in The Biochemistry of Smooth Muscle 1
(N. L. Stephens, ed. ), pp. 203-291, University Park Press, Baltimore, MD,
'
1977.

99.

Kreye, V.A.W. and Schultx, G., Eur. J. Pharmacol. 18:297, 1972.

100.

Hardman, J.G., Wells, J.N. and Hornet, P., in The Biochemistr; of Smooth
Muscle, (N.L. Stephens, ed.), pp. 329-341, University Park Press, Baltimore,
MD, 1977.

101.

Schramm, M, and Nairn, E. J. Bioi. Chern. 245:3225, 1970.

102.

Sands, H., Sinclair, D. and l·llascali, J., Blood Vessels 13:361, 1976.

103.

1-iynie, S. and Sharp, G.W.G., Biochimica et Biophysica Acta

104.

Perkins, J.P. and Moore, M.M., J. Bioi. Chern. 246:62, 1971.

~:1971.

